var title_f14_55_15216="Celiac disease capsule endoscopy";
var content_f14_55_15216=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F83586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F83586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Celiac disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Capsule endoscopy image in a patient with celiac disease. The findings are notable for villous blunting, leading to a scalloped mucosal appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_55_15216=[""].join("\n");
var outline_f14_55_15216=null;
var title_f14_55_15217="Skin and soft tissue infection (cellulitis)";
var content_f14_55_15217=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Skin and soft tissue infection (cellulitis) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/55/15217/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/55/15217/contributors\" id=\"au6903\">",
"       Larry M Baddour, MD, FIDSA",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/55/15217/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/55/15217/contributors\" id=\"se2060\">",
"       Daniel J Sexton, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?14/55/15217/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/55/15217/contributors\" id=\"de1811\">",
"       Elinor L Baron, MD, DTMH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?14/55/15217?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      SKIN INFECTION OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Cellulitis is an infection of the skin and soft tissue of the skin. The infection is usually caused by bacteria, such as staphylococci (\"Staph\") or streptococci (\"Strep\") that are commonly present on the skin or mucus membranes of the nose or mouth of otherwise normal and healthy people. The infection develops when there is a break in the skin, such as a wound or injury, which may be minor. This allows bacteria to enter the skin and grow, causing infection and swelling. &nbsp;",
"    </p>",
"    <p>",
"     Many cases of cellulitis are mild and heal completely with antibiotic treatment. However, some cases of cellulitis can be severe and lead to generalized infection. Thus it is important to seek medical care promptly if the infection is associated with fever, rapid worsening, other signs of progression of if you have other medical problems, such as diabetes.",
"    </p>",
"    <p>",
"     This topic discusses the symptoms and treatment of cellulitis. Other skin infections are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/4/22595?source=see_link\">",
"      \"Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/15/22770?source=see_link\">",
"      \"Patient information: Animal bites (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      SKIN INFECTION RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     Certain conditions increase the risk of developing cellulitis. These include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Recent injury to the skin (a wound, abrasion, cut, shaving, or injection drug use)",
"      </li>",
"      <li>",
"       Prior radiation therapy",
"      </li>",
"      <li>",
"       The presence of a fungal or viral skin infection, such as athlete's foot or chickenpox",
"      </li>",
"      <li>",
"       Accumulation of fluid (edema) due to poor circulation, heart failure, liver disease, or past surgery to remove lymph nodes",
"      </li>",
"      <li>",
"       Being overweight",
"      </li>",
"      <li>",
"       Chronic skin conditions, such as eczema &nbsp;",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     However, cellulitis can also develop in people who have no known risk factors. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link\">",
"      \"Cellulitis and erysipelas\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      SKIN INFECTION SYMPTOMS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Cellulitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common symptom of cellulitis is pain or tenderness. Other cellulitis symptoms can include swelling, warmth, and redness in a distinct area of skin. These symptoms commonly worsen and the redness may expand over the course of hours or days. The onset of cellulitis may be gradual or sudden. Itching is not a typical symptom of cellulitis. The skin is usually smooth and shiny, rather than raised or bumpy. However, occasionally in cases of cellulitis, blisters or small pimples may form in the skin.",
"    </p>",
"    <p>",
"     The most common areas of the body for cellulitis to develop include the legs and the arms; it can also develop around the eye, on the abdominal wall, in the mouth, and around the anus. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14803?source=see_link\">",
"      \"Cellulitis following pelvic lymph node dissection\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43991?source=see_link\">",
"      \"Breast cellulitis: Clinical manifestations, diagnosis, and management\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Other skin infections",
"     </span>",
"     &nbsp;&mdash;&nbsp;Other types of skin infections include abscesses, furuncles (\"boils\"), and carbuncles. These usually cause a collection of pus under the skin. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43831?source=see_link\">",
"      \"Skin abscesses, furuncles, and carbuncles\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Skin that is raised, reddened, tender, and pus-filled may be caused by a skin infection known as methicillin-resistant Staphylococcus aureus (MRSA). This is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/4/22595?source=see_link\">",
"      \"Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      DO I NEED TO BE EXAMINED?",
"     </span>",
"    </p>",
"    <p>",
"     There are many types and causes of skin infections, and it is important to know the most likely cause of the infection before beginning treatment. Using the wrong treatment could allow the infection to worsen. To ensure that the correct treatment is used, it is important to be evaluated by a healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      SKIN INFECTION TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Cellulitis treatment includes antibiotics as well as treatment of any underlying condition that led to the skin infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Elevate the area",
"     </span>",
"     &nbsp;&mdash;&nbsp;Elevating the arm or leg above the level of the heart can help to reduce swelling and speed healing.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Keep the area clean and dry",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is important to keep the infected area clean and dry. You can shower or bathe normally, and pat the area dry with a clean towel. You can use a bandage or gauze to protect the skin, if needed. Do not use any antibiotic ointments or creams.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Antibiotics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people with cellulitis are treated with an antibiotic that is taken by mouth for one to two weeks. The \"best\" antibiotic depends upon your situation.",
"    </p>",
"    <p>",
"     If the infection is severe, you may need to be hospitalized and treated with antibiotics given into a vein (IV).",
"    </p>",
"    <p>",
"     It is important to take the antibiotic exactly as recommended and to finish the entire course of treatment. Skipping doses or ending treatment early could potentially allow the bacteria to become resistant and require longer treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Time to heal",
"     </span>",
"     &nbsp;&mdash;&nbsp;The swelling, warmth, and redness should begin to improve within one to three days after starting antibiotics, although these symptoms can persist for two weeks. If the reddened area becomes larger, more swollen, or more tender, call your healthcare provider. He or she may want to reexamine you to determine if further testing or an alternate antibiotic are needed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H84511383\">",
"     <span class=\"h2\">",
"      Transmission to others",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most forms of cellulitis are not highly contagious to other family members. However, when you have cellulitis, it is important to wash your hands regularly with soap and water and to avoid sharing towels.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      SKIN INFECTION PROGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     In most cases, you will recover completely from an episode of cellulitis without any complications. If you have skin infection risk factors (see",
"     <a class=\"local\" href=\"#H2\">",
"      'Skin infection risk factors'",
"     </a>",
"     above), talk to your healthcare provider to determine if there are steps you can take to minimize the risk of infections in the future.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11284129\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11284136\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/23/4466?source=see_link\">",
"      Patient information: Cellulitis and erysipelas (skin infections) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/19/8498?source=see_link\">",
"      Patient information: Chronic granulomatous disease (The Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11284150\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/4/22595?source=see_link\">",
"      Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/15/22770?source=see_link\">",
"      Patient information: Animal bites (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11284384\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14803?source=see_link\">",
"      Cellulitis following pelvic lymph node dissection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/33/538?source=see_link\">",
"      Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/25/11674?source=see_link\">",
"      Orbital cellulitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43142?source=see_link\">",
"      Pseudomonas aeruginosa skin, soft tissue, and bone infections",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31687?source=see_link\">",
"      Soft tissue infections following water exposure",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43991?source=see_link\">",
"      Breast cellulitis: Clinical manifestations, diagnosis, and management",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43831?source=see_link\">",
"      Skin abscesses, furuncles, and carbuncles",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/000855.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/000855.htm",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Allergy and Infectious Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www3.niaid.nih.gov/topics/cellulitisErysipelas/\">",
"      www3.niaid.nih.gov/topics/cellulitisErysipelas/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://kidshealth.org/\">",
"        Kidshealth.org",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://kidshealth.org/parent/infections/bacterial_viral/cellulitis.html\">",
"      file://kidshealth.org/parent/infections/bacterial_viral/cellulitis.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?14/55/15217/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?14/55/15217?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15217/abstract/1\">",
"      Swartz MN. Clinical practice. Cellulitis. N Engl J Med 2004; 350:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15217/abstract/2\">",
"      Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15217/abstract/3\">",
"      Hepburn MJ, Dooley DP, Skidmore PJ, et al. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004; 164:1669.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f14_55_15217=[""].join("\n");
var outline_f14_55_15217=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           SKIN INFECTION OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           SKIN INFECTION RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           SKIN INFECTION SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           DO I NEED TO BE EXAMINED?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           SKIN INFECTION TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           SKIN INFECTION PROGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f14_55_15218="Wuchereria bancrofti smear";
var content_f14_55_15218=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 568px\">",
"   <div class=\"ttl\">",
"    Wuchereria bancrofti smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 548px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A, B) Microfilariae of",
"    <em>",
"     W. bancrofti",
"    </em>",
"    in thick blood smears stained with Giemsa. The organism has a sheath and no nuclei in its tail; body nuclei are distinct (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Filariasis. Available at:",
"     <a href=\"file://dpd.cdc.gov/dpdx/html/Filariasis.htm\" target=\"_blank\">",
"      file://dpd.cdc.gov/dpdx/html/Filariasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_55_15218=[""].join("\n");
var outline_f14_55_15218=null;
var title_f14_55_15219="Pityriasis alba 1";
var content_f14_55_15219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60866%7EDERM%2F73576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60866%7EDERM%2F73576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pityriasis alba",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hypopigmented macules are present on the face of this young girl with pityriasis alba.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Nicole Sorensen, RN, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pityriasis alba",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pityriasis alba. Hypopigmented, slightly scaly macules are present on this child's cheeks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_55_15219=[""].join("\n");
var outline_f14_55_15219=null;
var title_f14_55_15220="Calcitonin: Pediatric drug information";
var content_f14_55_15220=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Calcitonin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"    see \"Calcitonin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/48/37636?source=see_link\">",
"    see \"Calcitonin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fortical&reg;;",
"     </li>",
"     <li>",
"      Miacalcin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F144122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Calcitonin&reg;;",
"     </li>",
"     <li>",
"      Calcimar&reg;;",
"     </li>",
"     <li>",
"      Caltine&reg;;",
"     </li>",
"     <li>",
"      Miacalcin&reg; NS;",
"     </li>",
"     <li>",
"      PRO-Calcitonin;",
"     </li>",
"     <li>",
"      Sandoz-Calcitonin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Hypercalcemia",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"      see \"Calcitonin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &gt;6 months and adults: Osteogenesis imperfecta: I.M., SubQ: 2 international units/kg 3 times/week (Castells, 1979)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Paget's disease: I.M., SubQ: Initial: 100 international units/day; maintenance dose: 50 international units/day or 50-100 international units every 1-2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hypercalcemia: Initial: I.M., SubQ: 4 international units/kg every 12 hours for 1-2 days; may increase up to 8 international units/kg every 12 hours; if the response remains unsatisfactory after 2 additional days, a further increase up to a maximum of 8 international units/kg every 6 hours may be considered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Postmenopausal osteoporosis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.M., SubQ: 100 international units every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Intranasal: 200 international units (1 spray) into",
"     <b>",
"      one",
"     </b>",
"     nostril daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [calcitonin-salmon]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miacalcin&reg;: 200 units/mL (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [calcitonin-salmon/rDNA origin/spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fortical&reg;: 200 units/actuation (3.7 mL) [contains benzyl alcohol; delivers 30 doses]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [calcitonin-salmon/spray]: 200 units/actuation (3.7 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miacalcin&reg;: 200 units/actuation (3.7 mL) [contains benzalkonium chloride; delivers 30 doses]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Intranasal solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intranasal: Spray into",
"     <b>",
"      one",
"     </b>",
"     nostril daily; alternate nostrils to reduce irritation. Before priming a new pump, allow it to reach room temperature first.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Do not exceed 2 mL volume per injection site; may be administered SubQ or I.M. SubQ is preferred for outpatient self administration; I.M. is preferred for larger injection volumes.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1057070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: Store under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); protect from freezing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nasal: Store unopened bottle under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fortical&reg;: After opening, store for up to 30 days at 20��C to 25��C (68��F to 77��F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Store in upright position.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miacalcin&reg;: After opening, store for up to 35 days at room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Store in upright position.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Treatment of Paget's disease of bone; adjunctive therapy for hypercalcemia; postmenopausal osteoporosis (FDA approved in adults); has also been used for osteogenesis imperfecta",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intranasal: Postmenopausal osteoporosis in women &gt;5 years postmenopause with low bone mass (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F144173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Calcitonin may be confused with calcitriol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Miacalcin&reg; may be confused with Micatin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Calcitonin nasal spray is administered as a single spray into",
"       <b>",
"        one",
"       </b>",
"       nostril daily, using alternate nostrils each day.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F144171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, flushing, hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Depression, dizziness, fatigue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythematous rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Cystitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthrosis, back pain, myalgia, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis, lacrimation abnormality",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, nasal ulcerations, rhinitis (including ulcerative), sinusitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome, infection, lymphadenopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening): Agitation, allergic reactions, allergic rhinitis, alopecia, anaphylactoid reaction, anaphylaxis/anaphylactic shock, anemia, anorexia, anxiety, appetite increased, arthralgia, arthritis, blurred vision, bronchitis, bundle branch block, cerebrovascular accident, cholelithiasis, cough, diaphoresis, dyspnea, earache, eczema, edema, eye pain, fever, flatulence, gastritis, goiter, hearing loss, hematuria, hepatitis, hypersensitivity, hyperthyroidism, insomnia, malignancy, migraine, mucosal excoriation, myocardial infarction, nasal congestion, nasal odor, neuralgia, nocturia, palpitation, parosmia, periorbital edema, pharyngitis, pneumonia, polymyalgia rheumatica, polyuria, pruritus, pyelonephritis, rash, renal calculus, skin ulceration, sneezing, stiffness, tachycardia, taste perversion, thirst, thrombophlebitis, tinnitus, tremor, urine sediment abnormality, vertigo, visual disturbances, vitreous floater, vomiting, weight gain, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to calcitonin, salmon protein, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1057067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to potential hypersensitivity reactions, a skin test is recommended prior to initiating parenteral therapy; the skin test is 0.1 mL of 10 unit/mL calcitonin injection in NS (must be prepared) injected intradermally; observe injection site for 15 minutes for wheal or significant erythema; when using intranasal formulation, periodic nasal examinations are recommended. Discontinue for nasal ulcerations &gt;1.5 mm or those that penetrate below the mucosa.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Calcitonin may decrease the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F144095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1861980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreased birth weight was observed in animal reproduction studies. Calcitonin does not cross the placenta. The nasal spray formulations are not indicated for use in pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1057073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum electrolytes and calcium; alkaline phosphatase and 24-hour urine collection for hydroxyproline excretion (Paget's disease); urinalysis (urine sediment); serum calcium; periodic nasal exams (intranasal use only)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcitonin directly inhibits osteoclastic bone resorption; promotes the renal excretion of calcium, phosphate, sodium, magnesium and potassium by decreasing tubular reabsorption; increases the jejunal secretion of water, sodium, potassium, and chloride",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1057080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypercalcemia: I.M., SubQ: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Paget&rsquo;s disease: Within a few months; may take up to 1 year for neurologic symptom improvement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Hypercalcemia: I.M., SubQ: 6-8 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1057081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Intranasal: Rapidly but highly variable and lower than I.M. administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapidly in the kidneys, blood, and peripheral tissues",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: I.M. 66%; SubQ: 71%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination (terminal): I.M.: 58 minutes; SubQ: 59-64 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: SubQ ~23 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: As inactive metabolites in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Salmon calcitonin: 3.1 mL/kg/minute",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1057072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/48/37636?source=see_link\">",
"      see \"Calcitonin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nasal spray: Notify physician if you develop significant nasal irritation; alternate nostrils; in treatment of postmenopausal osteoporosis, maintain adequate vitamin D intake and supplemental calcium",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Castells S, Colbert C, Chakrabarti C, et al, \"Therapy of Osteogenesis Imperfecta With Synthetic Salmon Calcitonin,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1979, 95(5 Pt 1):807-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15220/abstract-text/573785/pubmed\" id=\"573785\" target=\"_blank\">",
"        573785",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13106 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-A3F5C7E4D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_55_15220=[""].join("\n");
var outline_f14_55_15220=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144121\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144122\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057074\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057068\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144099\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144084\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057078\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057070\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057077\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144173\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144171\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057082\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057067\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298928\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218757\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144095\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1861980\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057073\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057066\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057080\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057081\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057072\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13106\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13106|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=related_link\">",
"      Calcitonin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/48/37636?source=related_link\">",
"      Calcitonin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_55_15221="Benzoyl peroxide: Patient drug information";
var content_f14_55_15221=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Benzoyl peroxide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/24/42373?source=see_link\">",
"     see \"Benzoyl peroxide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/60/18372?source=see_link\">",
"     see \"Benzoyl peroxide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F140054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Acne Clear Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      BenzEFoam Ultra&trade;;",
"     </li>",
"     <li>",
"      BenzEFoam&trade;;",
"     </li>",
"     <li>",
"      Benziq&trade;;",
"     </li>",
"     <li>",
"      BP Cleanser [OTC];",
"     </li>",
"     <li>",
"      BP Cleansing Lotion [OTC];",
"     </li>",
"     <li>",
"      BP Wash [OTC];",
"     </li>",
"     <li>",
"      BPO;",
"     </li>",
"     <li>",
"      Clean &amp; Clear&reg; advantage&reg; 3-in-1 [OTC];",
"     </li>",
"     <li>",
"      Clean &amp; Clear&reg; continuous control&reg; [OTC];",
"     </li>",
"     <li>",
"      Clean &amp; Clear&reg; persa-gel&reg; 10 [OTC];",
"     </li>",
"     <li>",
"      Clearskin [OTC];",
"     </li>",
"     <li>",
"      Desquam-X&reg; 10 [OTC];",
"     </li>",
"     <li>",
"      Desquam-X&reg; 5 [OTC];",
"     </li>",
"     <li>",
"      Inova&reg;;",
"     </li>",
"     <li>",
"      Neutrogena&reg; On The Spot&reg; Acne Treatment [OTC];",
"     </li>",
"     <li>",
"      OXY&reg; Clinical Clearing Treatment [OTC];",
"     </li>",
"     <li>",
"      OXY&reg; Maximum Face Wash [OTC];",
"     </li>",
"     <li>",
"      OXY&reg; Maximum Spot Treatment [OTC];",
"     </li>",
"     <li>",
"      Pacnex&reg;;",
"     </li>",
"     <li>",
"      Pacnex&reg; HP;",
"     </li>",
"     <li>",
"      Pacnex&reg; LP;",
"     </li>",
"     <li>",
"      PanOxyl&reg; Bar [OTC];",
"     </li>",
"     <li>",
"      PanOxyl&reg; [OTC];",
"     </li>",
"     <li>",
"      PanOxyl&reg;-4 [OTC];",
"     </li>",
"     <li>",
"      PanOxyl&reg;-8 [OTC];",
"     </li>",
"     <li>",
"      PR&trade; Wash;",
"     </li>",
"     <li>",
"      SE BPO;",
"     </li>",
"     <li>",
"      TL BPO MX;",
"     </li>",
"     <li>",
"      Zapzyt&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F140055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Acetoxyl&reg;;",
"     </li>",
"     <li>",
"      Benoxyl&reg;;",
"     </li>",
"     <li>",
"      Benzac AC&reg;;",
"     </li>",
"     <li>",
"      Benzac W&reg; Gel;",
"     </li>",
"     <li>",
"      Benzac W&reg; Wash;",
"     </li>",
"     <li>",
"      Desquam-X&reg;;",
"     </li>",
"     <li>",
"      Oxyderm&trade;;",
"     </li>",
"     <li>",
"      PanOxyl&reg;;",
"     </li>",
"     <li>",
"      Solugel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pimples (acne).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701606",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to benzoyl peroxide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use of other skin products may cause more irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697705",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may stain clothing or fabric.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697667",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may stain hair.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697946",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696388",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake foam and lotion well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695334",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Makeup may be used after the skin has dried.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705353",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Cleanser:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696242",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash and rinse affected skin with warm water, then pat dry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705354",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Cloth:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696390",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wet cloth with water and work into lather.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696389",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your face with a cloth for 10 to 20 seconds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696386",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse face and pat dry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Face mask:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696226",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wait 15 to 25 minutes for the mask to dry, then rinse with warm water, and pat dry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705527",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shaving cream:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wet affected part and put on a thin layer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695642",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shave, rinse with warm water, and pat dry.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11471 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-298F256B3B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_55_15221=[""].join("\n");
var outline_f14_55_15221=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140054\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140055\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024022\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024021\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024026\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024027\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024029\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024024\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024025\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024030\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024031\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/24/42373?source=related_link\">",
"      Benzoyl peroxide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/60/18372?source=related_link\">",
"      Benzoyl peroxide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_55_15222="Uterine blood supply";
var content_f14_55_15222=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Uterine blood supply",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 495px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_55_15222=[""].join("\n");
var outline_f14_55_15222=null;
var title_f14_55_15223="Chlamydia conjunctivitis";
var content_f14_55_15223=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F84033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F84033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Chlamydia conjunctivitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 369px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the Seattle STD/HIV Prevention Training Center.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_55_15223=[""].join("\n");
var outline_f14_55_15223=null;
var title_f14_55_15224="Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oropharynx";
var content_f14_55_15224=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oropharynx",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/55/15224/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/55/15224/contributors\">",
"     Francis P Worden, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/55/15224/contributors\">",
"     Carol R Bradford, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/55/15224/contributors\">",
"     Avraham Eisbruch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/55/15224/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/55/15224/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/55/15224/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/55/15224/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/55/15224/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/55/15224/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/55/15224/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oropharyngeal squamous cell carcinomas originate in the soft palate, tonsils, base of tongue, pharyngeal wall, or the vallecula, the fold located between the base of tongue and the epiglottis (",
"    <a class=\"graphic graphic_figure graphicRef75396 \" href=\"UTD.htm?26/56/27525\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/1\">",
"     1",
"    </a>",
"    ]. Oropharyngeal cancer is a relatively uncommon malignancy, with approximately 123,000 cases of oropharyngeal and hypopharyngeal cancer diagnosed worldwide each year, which cause about 79,000 deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Historically, tobacco and alcohol were the principal risk factors associated with oropharyngeal cancer. However, there has been a shift in the epidemiology of this disease, with a significant increase in cases due to human papillomavirus (HPV) infection and a decrease in cases associated with tobacco and alcohol [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/3\">",
"     3",
"    </a>",
"    ]. These HPV associated cancers predominantly arise in the oropharynx, particularly the tonsillar area and the tongue base. Although these tumors have significant differences compared with other cancers arising in this area, including better prognosis, there is no evidence to indicate that treatment is different from that with other oropharyngeal tumors. Current clinical trials either stratify for HPV status or are designed specifically for patients with HPV associated cancer, to answer questions related to minimizing treatment-related toxicities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=see_link\">",
"     \"Human papillomavirus associated head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The tumor node metastasis (TNM) staging system of the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC) is used to stage oropharyngeal cancer (",
"    <a class=\"graphic graphic_table graphicRef81775 \" href=\"UTD.htm?35/55/36733\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef54099 \" href=\"UTD.htm?8/3/8244\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=see_link\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of locally advanced, stage III to IVB (",
"    <a class=\"graphic graphic_table graphicRef81775 \" href=\"UTD.htm?35/55/36733\">",
"     table 1",
"    </a>",
"    ), cancers of the oropharynx will be reviewed here. The treatment of early stage oropharyngeal cancer is discussed separately, as is the management of patients with distant metastases (stage IVC).",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3174?source=see_link&amp;anchor=H636375187#H636375187\">",
"       \"Treatment of early (stage I and II) head and neck cancer: The oropharynx\", section on 'General principles'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=see_link\">",
"       \"Treatment of metastatic and recurrent head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NONSURGICAL VERSUS SURGICAL APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Locally advanced oropharyngeal cancer (stages III and",
"    <span class=\"nowrap\">",
"     IVA/B)",
"    </span>",
"    includes T3 or T4 primary tumors without lymph node involvement and T1 or greater tumors with cervical node involvement but without distant metastases (",
"    <a class=\"graphic graphic_table graphicRef81775 \" href=\"UTD.htm?35/55/36733\">",
"     table 1",
"    </a>",
"    ). Treatment requires a multidisciplinary team approach to provide optimal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Selecting between nonsurgical organ-sparing approaches and primary surgery as the most appropriate treatment for patients with locally advanced, resectable oropharyngeal cancer is complex. There are no large randomized trials that compare functional organ preservation using a combination of chemotherapy plus RT versus an initial surgical approach followed by radiation or chemoradiotherapy in patients with locally advanced oropharyngeal cancer.",
"   </p>",
"   <p>",
"    Although functional organ preservation approaches are widely used, surgery followed by either postoperative radiation therapy (RT) or concurrent chemoradiotherapy is an alternative in appropriately selected patients. For patients with unresectable (T4b) disease, a combined modality approach that includes chemotherapy plus RT, given either sequentially",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    concurrently, is used. (See",
"    <a class=\"local\" href=\"#H950792255\">",
"     'Functional organ preservation approaches'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13562838\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H950792255\">",
"    <span class=\"h1\">",
"     FUNCTIONAL ORGAN PRESERVATION APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with potentially resectable disease, nonsurgical functional organ preservation approaches that include both chemotherapy and RT are generally used, even when gross removal of the entire tumor with acceptable functional and cosmetic outcomes is thought to be feasible. However, there are no large randomized trials comparing these approaches with a combined modality approach that includes surgery. (See",
"    <a class=\"local\" href=\"#H13562838\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The optimal agents and schedule are controversial and are discussed in detail separately. This discussion will focus on the application of those approaches to patients with a primary carcinoma of the oropharynx. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chemotherapy plus RT versus RT alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous clinical trials in patients with locally or regionally advanced squamous cell carcinoma of the head and neck have established the role of combinations of chemotherapy and radiotherapy as a functional organ preservation technique.",
"   </p>",
"   <p>",
"    The most extensive data supporting these approaches come from the Meta-Analysis of Chemotherapy on Head and Neck Cancer (MACH-NC) that included trials in which the chemotherapy was given as a neoadjuvant, concurrently with RT, or as an adjuvant following definitive locoregional therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/5\">",
"     5",
"    </a>",
"    ]. An analysis from the MACH-NC group confirmed that treatment regimens that included both chemotherapy and RT significantly decreased the risk of death in 5872 patients with oropharyngeal carcinoma compared with RT alone (hazard ratio [HR] 0.88, 95% CI 0.82-0.93). This corresponded to an absolute improvement of 5 percent in overall survival at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link&amp;anchor=H281026429#H281026429\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\", section on 'Definitive locoregional therapy alone vs chemotherapy plus definitive locoregional therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the benefit observed in this meta-analysis was limited to concurrent chemoradiotherapy, these analyses did not include several large contemporary trials that utilized induction chemotherapy regimens containing platinum plus 5-fluorouracil or platinum, 5-fluorouracil, plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    . Contemporary trials have explored alternative schedules and regimens for combined modality therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Contemporary trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platinum-based chemotherapy is the standard of care for regimens combining chemotherapy and RT. In the MACH-NC meta-analysis comparing different chemotherapy regimens, platinum-based chemotherapy was superior to non-platinum based regimens; there was a trend but no significant difference between single-agent and multiagent concurrent chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/5\">",
"     5",
"    </a>",
"    ]. Whether sequential therapy provides a survival advantage compared with concurrent chemoradiotherapy alone is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H521750111\">",
"    <span class=\"h3\">",
"     Induction chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of neoadjuvant chemotherapy on survival in oropharyngeal cancer was demonstrated in a French trial in which 318 patients were randomly assigned to three cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus a five-day intravenous infusion of 5-fluorouracil or definitive locoregional therapy without neoadjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/8\">",
"     8",
"    </a>",
"    ]. Overall survival was significantly better in those given neoadjuvant chemotherapy compared with those treated with definitive locoregional therapy alone (median survival 5.1 versus 3.3 years).",
"   </p>",
"   <p>",
"    Two other trials, TAX 324 and TAX 323 provide additional indirect evidence for the role of induction chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. These trials also demonstrated that the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    to an induction regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus 5-fluorouracil was more effective than cisplatin plus 5-fluorouracil alone. Approximately one-half of the patients in these two trials had oropharyngeal cancer. These trials are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link&amp;anchor=H281026593#H281026593\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\", section on 'Induction chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H521750118\">",
"    <span class=\"h3\">",
"     Concurrent chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every 21 days for three doses) is the most widely studied chemotherapy regimen for use in combination with conventionally fractionated RT. A number of other regimens have been used, including weekly or daily cisplatin.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     Carboplatin",
"    </a>",
"    in combination with 5-fluorouracil has also been used [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/7\">",
"     7",
"    </a>",
"    ]. Weekly carboplatin (area under the concentration x time curve [AUC] of 1.5 to 2) given concurrently with RT may be a particularly useful option for patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    as a part of an induction chemotherapy regimen.",
"   </p>",
"   <p>",
"    The regimens for concurrent chemotherapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link&amp;anchor=H281027161#H281027161\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\", section on 'Concurrent chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Cetuximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    is a recombinant monoclonal antibody that competitively inhibits natural ligands of the epidermal growth factor receptor (EGFR).",
"   </p>",
"   <p>",
"    Concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    plus RT was evaluated in a multinational randomized study of patients with locoregionally advanced head and neck cancer, in which approximately 60 percent of patients had oropharyngeal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/11\">",
"     11",
"    </a>",
"    ]. The addition of cetuximab improved both locoregional control and overall survival compared with RT alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link&amp;anchor=H168427307#H168427307\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\", section on 'Cetuximab alone plus RT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    does not yet have an established role as preferred therapy in combination with RT. Subset analyses showed that the benefit of cetuximab plus RT was restricted to patients less than age 65 years and with a Karnofsky performance score (KPS) 90 to 100 (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"     table 2",
"    </a>",
"    ), although the trial was not powered to analyze these subsets. Overall survival was better with RT alone in patients 65 years of age and older and those with KPS 60 to 80, although these differences were not statistically significant. Thus, the data do not support the use of cetuximab with RT as an alternative to RT alone in elderly patients and those with significant comorbidities where concurrent platinum chemotherapy is not feasible. Longer follow-up from this trial may clarify these results.",
"   </p>",
"   <p>",
"    Furthermore, there are no results from clinical trials that compare",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    plus RT versus a platinum compound plus RT. The RTOG is currently conducting a phase III trial in which patients with locally advanced p16+ oropharyngeal cancer are treated with intensity modulated RT (IMRT) and randomly assigned to either concurrent cetuximab (weekly) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (on days 1 and 22) (RTOG 1016, NCT01302834) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, preliminary data indicate that combining",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    plus a platinum as concurrent therapy during RT is no better than treatment with a platinum alone [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link&amp;anchor=H168427314#H168427314\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\", section on 'Cetuximab plus cisplatin plus RT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Radiation schedule and technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard RT approach for patients treated with concurrent chemoradiotherapy is to use once daily fractionation with three-dimensional conformal treatment planning (3D-CRT), generally including intensity-modulated RT (IMRT), and image-guided RT (IGRT). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=see_link&amp;anchor=H163948839#H163948839\">",
"     \"General principles of radiation therapy for head and neck cancer\", section on 'Three-dimensional conformal RT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Altered-fractionation RT schedules, including accelerated RT and hyperfractionation, have been investigated to overcome accelerated repopulation and to safely escalate the dose. Hyperfractionation regimens appear to improve both local control and overall survival when compared with once daily (conventional) fractionation RT when given without concurrent chemotherapy. Accelerated fractionation improves local-regional control, but its effect on overall survival is less clear [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link&amp;anchor=H99325300#H99325300\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\", section on 'Hyperfractionation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link&amp;anchor=H1493367204#H1493367204\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\", section on 'Accelerated fractionation RT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Furthermore, twice daily treatment schedules place greater time demands on the patient and the treatment facility, and may create problems with compliance. Recently, the RTOG 0129 trial compared standard fractionation RT and concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    with accelerated fractionation RT and cisplatin and found that the two treatment schedules were equivalent to one another [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/15\">",
"     15",
"    </a>",
"    ]. The results of this trial are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link&amp;anchor=H281026895#H281026895\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\", section on 'Cisplatin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dysphagia is an important complication of RT for patients treated for oropharyngeal cancer. Preliminary data suggest that intensity modulated RT (IMRT) might minimize the risk of this complication. In a prospective study of 73 patients being treated for oropharyngeal cancer, IMRT was combined with weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/16\">",
"     16",
"    </a>",
"    ]. This study excluded patients with involvement of medial retropharyngeal lymph nodes, and thus the dose of radiation to the pharyngeal constrictors was limited. At one year after treatment, dysphagia was present in only four patients, one of whom was dependent upon a feeding tube and three who required a soft diet. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link&amp;anchor=H3822602#H3822602\">",
"     \"Management of late complications of head and neck cancer and its treatment\", section on 'Esophageal toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13562838\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transoral robotic surgery (TORS) and laser approaches have emerged that allow adequate visualization and exposure of oropharyngeal primary tumors without the morbidity of mandibulotomy and lip split approaches. These approaches are most feasible for early T stage tumors of the oropharynx",
"    <span class=\"nowrap\">",
"     (T1/T2)",
"    </span>",
"    and become more challenging with advanced T stages, particularly for those tumors with mandibular involvement.",
"   </p>",
"   <p>",
"    When early primary stage is accompanied by advanced nodal staging, controversy exists over the best treatment approach. Since many of these patients will require adjuvant chemoradiation for their advanced nodal stage disease, the question arises whether transoral approaches add benefit to those patients who may be cured by chemoradiation alone. Active investigation is ongoing in this area.",
"   </p>",
"   <p>",
"    Most surgeons favor composite resection (mandibulectomy) for tumors with gross bony involvement. While prospective randomized trials are lacking, gross mandibular invasion is difficult to cure with nonsurgical approaches and, in many cases, leads to osteoradionecrosis due to high doses of radiation to the mandible. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H430870141\">",
"    <span class=\"h1\">",
"     ELDERLY AND POOR PERFORMANCE STATUS PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemoradiotherapy is often avoided in elderly patients with advanced oropharyngeal cancer as well as in those with a poor performance status since the use of concurrent chemotherapy may delay or prevent the completion of a course of definitive RT.",
"   </p>",
"   <p>",
"    Concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    may be less toxic than a platinum compound [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/11\">",
"     11",
"    </a>",
"    ]. However, the limited available evidence suggests that this approach is not more effective than RT alone in these patient subsets, although the trial was not powered adequately for subset analyses. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Cetuximab'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients who are not candidates for concurrent chemoradiotherapy because of age or comorbidity, definitive RT alone remains a treatment option. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link&amp;anchor=H1049946406#H1049946406\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\", section on 'Patient selection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SURGICAL MANAGEMENT OF THE NECK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of the neck in patients with head and neck cancer is complex. The risk of residual occult disease must be balanced against the complications of treatment, which can include either neck dissection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    irradiation. The choice of treatment depends upon the extent of disease, the treatment modality used to treat the primary tumor, and the response to therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link&amp;anchor=H281028079#H281028079\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\", section on 'Management of the neck'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184285100\">",
"    <span class=\"h2\">",
"     After definitive chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A posttreatment neck dissection is indicated for patients with clinically evident cervical lymph nodes who have an incomplete clinical response to therapy.",
"   </p>",
"   <p>",
"    Controversy exists as to whether or not a posttreatment neck dissection is indicated for all patients with initial N3 disease who achieve a complete response or whether observation is appropriate in the presence of a PET",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CT based complete response [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/17\">",
"     17",
"    </a>",
"    ]. Observation of N2 disease following concurrent chemoradiotherapy or sequential therapy is a reasonable approach if clinical examination and imaging studies show a complete response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     After primary surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgical approach to the neck in a patient who has undergone surgery as management of their primary oropharyngeal cancer is determined by the extent of regional lymph node involvement:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Clinically negative cervical nodes (N0)",
"      </strong>",
"      &mdash; Prophylactic selective neck dissection, including lymph node levels I-IV, is one approach for patients with T3 and T4 tumors with clinically negative cervical nodes (N0) (",
"      <a class=\"graphic graphic_table graphicRef81775 \" href=\"UTD.htm?35/55/36733\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef54099 \" href=\"UTD.htm?8/3/8244\">",
"       figure 2",
"      </a>",
"      ). Although bilateral treatment is recommended for midline lesions, ipsilateral neck treatment is sufficient in other cases. An alternative approach for the N0 neck is neck irradiation, particularly if the primary site requires adjuvant RT.",
"     </li>",
"     <li>",
"      <strong>",
"       Clinical N1 disease",
"      </strong>",
"      &mdash; The suggested treatment for early nodal disease (N1, metastasis in a single node &le;3 cm) is a selective neck dissection (including levels I-IV).",
"     </li>",
"     <li>",
"      <strong>",
"       Clinical",
"      </strong>",
"      <strong>",
"       N2 or N3 disease",
"      </strong>",
"      &mdash; A modified radical neck dissection should be performed when surgery is used for the primary treatment in patients with oropharyngeal cancer and advanced nodal disease (N2 and N3).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no randomized trials comparing selective neck dissection with modified radical neck dissection. In a review of patients with head and neck cancer and N0-N2 disease, the three-year rates of neck recurrence for pathologic pN1 and pN2 disease following selective neck dissection were similar to the rates of recurrence in historical controls who underwent modified radical neck dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/18\">",
"     18",
"    </a>",
"    ]. This has led some to suggest that selective neck dissection is adequate in patients with pathologic node-positive neck disease. In contrast, analysis of combined data from several large studies of selective neck dissection and modified radical neck dissection revealed a statistically significant lower recurrence rate in patients treated with modified radical neck dissection versus selective neck dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications from concurrent chemoradiation and surgery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Surveillance, Epidemiology and End Results (SEER) Cancer Statistics review for the years 1988 to 2004 reports a five-year relative survival for locoregionally advanced disease and all stages of oropharyngeal cancer of 40 and 53 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/20\">",
"     20",
"    </a>",
"    ]. Analysis of this same database suggests an improvement over time in five-year survival for both locoregional and all stage oropharyngeal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple studies have shown that HPV related oropharyngeal cancers have a better prognosis than those not associated with HPV. The overall improvement in survival for oropharyngeal cancer may be due to this epidemiologic shift [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In large trials of patients with locoregionally advanced HPV positive oropharyngeal cancer, long term survival rates of approximately 80 percent have been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/9,24-27\">",
"     9,24-27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=see_link\">",
"     \"Human papillomavirus associated head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     POSTTREATMENT EVALUATION AND SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular posttreatment follow-up is an essential part of the care of patients after potentially curative treatment of head and neck cancer both to detect recurrent disease and to diagnose second malignancies that may develop. Preliminary data suggest that there is a decreased risk of relapse and second primaries in patients with HPV related oropharyngeal cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15270?source=see_link\">",
"     \"Second primary malignancies in patients with head and neck cancers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=see_link\">",
"     \"Human papillomavirus associated head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients treated with concurrent chemoradiotherapy or sequential chemoradiotherapy, assessment to ensure the absence of residual disease is critical. The clinical examination is combined with imaging studies, particularly contrast enhanced computed tomography (CT), and positron emission tomography (PET). Such imaging studies can be difficult to interpret if they are performed too soon (eg, PET prior to 12 weeks) after the completion of concurrent chemoradiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15224/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=see_link\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, the intensity of follow-up is greatest in the first two to four years following diagnosis, since approximately 80 to 90 percent of all recurrences occur within this timeframe. Continued follow-up beyond five years is generally recommended because of the risk of late complications, as well as the risk of late recurrence or second malignancies, particularly in patients with non-HPV associated oropharyngeal cancers.",
"   </p>",
"   <p>",
"    Posttreatment surveillance of head and neck cancer, including screening for treatment-related complications, is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=see_link\">",
"     \"Posttreatment surveillance of squamous carcinoma of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oropharyngeal squamous cell carcinomas arise in the soft palate, tonsils, base of tongue, pharyngeal wall, or vallecula (",
"      <a class=\"graphic graphic_table graphicRef81775 \" href=\"UTD.htm?35/55/36733\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef65105 \" href=\"UTD.htm?1/5/1113\">",
"       figure 3",
"      </a>",
"      ). There has been a dramatic demographic shift from carcinogen related (tobacco and alcohol) to HPV related oropharyngeal cancers, which arise primarily in the tonsils and base of tongue. These HPV associated oropharyngeal cancers have a better prognosis than other oropharyngeal cancers, but there is no evidence that the optimal approach to treatment differs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=see_link\">",
"       \"Human papillomavirus associated head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Locally advanced oropharyngeal cancers (stages III and",
"      <span class=\"nowrap\">",
"       IVA/B)",
"      </span>",
"      include T3 or T4 primary tumors without lymph node involvement and T1 or greater tumors with cervical node involvement but without distant metastases (",
"      <a class=\"graphic graphic_table graphicRef81775 \" href=\"UTD.htm?35/55/36733\">",
"       table 1",
"      </a>",
"      ). Treatment of locally advanced oropharyngeal cancer (stages III and",
"      <span class=\"nowrap\">",
"       IVA/B)",
"      </span>",
"      requires a multidisciplinary team approach. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nonsurgical versus surgical approaches'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with potentially resectable, locally advanced oropharyngeal cancer, functional organ preservation approaches combining radiation therapy (RT) with chemotherapy and surgery followed by radiation therapy (RT) or chemoradiotherapy are acceptable options. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nonsurgical versus surgical approaches'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients treated with primary surgery, we recommend postoperative RT or chemoradiotherapy for those with high-risk features (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nonsurgical versus surgical approaches'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13562838\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with unresectable lesions, we suggest treatment with a combined modality approach including both chemotherapy and radiotherapy rather than RT alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Chemotherapy plus RT versus RT alone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal approach to combining RT and chemotherapy including sequencing of treatments and choice of agents is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=see_link\">",
"       \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Management of the neck is complex and depends upon disease extent, treatment modality used to treat the primary tumor, and response to therapy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Surgical management of the neck'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/2\">",
"      Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/3\">",
"      Sturgis EM, Ang KK. The epidemic of HPV-associated oropharyngeal cancer is here: is it time to change our treatment paradigms? J Natl Compr Canc Netw 2011; 9:665.",
"     </a>",
"    </li>",
"    <li>",
"     NCCN Clinical Practice Guidelines, Head and Neck Cancers file://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/5\">",
"      Pignon JP, le Ma&icirc;tre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/6\">",
"      Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol 2011; 100:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/7\">",
"      Bourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol 2012; 13:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/8\">",
"      Domenge C, Hill C, Lefebvre JL, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la T&ecirc;te et du Cou (GETTEC). Br J Cancer 2000; 83:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/9\">",
"      Lorch JH, Goloubeva O, Haddad RI, et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 2011; 12:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/10\">",
"      Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/11\">",
"      Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567.",
"     </a>",
"    </li>",
"    <li>",
"     NIH Clinical trials database. file://www.clinicaltrials.gov/.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/13\">",
"      Ang KK, et AL. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (abstract #5500). J Clin Oncol 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/14\">",
"      Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006; 368:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/15\">",
"      Ang K, Zhang Q, Wheeler RH, et al. A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): Impact of radiation and cisplatin intensity on outcome (abstract #5507). J Clin Oncol 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/16\">",
"      Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol 2010; 28:2732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/17\">",
"      Porceddu SV, Pryor DI, Burmeister E, et al. Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head Neck 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/18\">",
"      Paccagnella A, Buffoli A, Koussis H, et al. Concomitant chemoradiotherapy versus neoadjuvant chemotherapy with docetaxel, cisplatin, 5-fluorouracil (TPF) followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2008; 26:6000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/19\">",
"      Leemans CR, Tiwari R, van der Waal I, et al. The efficacy of comprehensive neck dissection with or without postoperative radiotherapy in nodal metastases of squamous cell carcinoma of the upper respiratory and digestive tracts. Laryngoscope 1990; 100:1194.",
"     </a>",
"    </li>",
"    <li>",
"     Ries LG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD file://seer.cancer.gov/csr/1975_2005/ (Accessed on March 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/21\">",
"      Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 2005; 114:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/22\">",
"      Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006; 24:5630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/23\">",
"      Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/24\">",
"      Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/25\">",
"      Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010; 28:4142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/26\">",
"      Posner MR, Lorch JH, Goloubeva O, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 2011; 22:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/27\">",
"      Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29:4294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15224/abstract/28\">",
"      Ljumanovic R, Langendijk JA, Hoekstra OS, et al. Pre- and post-radiotherapy MRI results as a predictive model for response in laryngeal carcinoma. Eur Radiol 2008; 18:2231.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3385 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-E9F4F161E5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_55_15224=[""].join("\n");
var outline_f14_55_15224=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NONSURGICAL VERSUS SURGICAL APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H950792255\">",
"      FUNCTIONAL ORGAN PRESERVATION APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chemotherapy plus RT versus RT alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Contemporary trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H521750111\">",
"      - Induction chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H521750118\">",
"      - Concurrent chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cetuximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Radiation schedule and technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13562838\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H430870141\">",
"      ELDERLY AND POOR PERFORMANCE STATUS PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SURGICAL MANAGEMENT OF THE NECK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H184285100\">",
"      After definitive chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      After primary surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      POSTTREATMENT EVALUATION AND SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3385\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3385|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/56/27525\" title=\"figure 1\">",
"      Anatomy of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/3/8244\" title=\"figure 2\">",
"      Lymph node levels of the neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/5/1113\" title=\"figure 3\">",
"      Subdivisions pharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3385|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/55/36733\" title=\"table 1\">",
"      TNM stage oropharynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 2\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=related_link\">",
"      Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=related_link\">",
"      General principles of radiation therapy for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=related_link\">",
"      Human papillomavirus associated head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=related_link\">",
"      Overview of the diagnosis and staging of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=related_link\">",
"      Posttreatment surveillance of squamous carcinoma of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15270?source=related_link\">",
"      Second primary malignancies in patients with head and neck cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3174?source=related_link\">",
"      Treatment of early (stage I and II) head and neck cancer: The oropharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=related_link\">",
"      Treatment of metastatic and recurrent head and neck cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_55_15225="General principles of insulin therapy in diabetes mellitus";
var content_f14_55_15225=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   General principles of insulin therapy in diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/55/15225/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/55/15225/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/55/15225/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/55/15225/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/55/15225/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/55/15225/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/55/15225/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin is used in the treatment of patients with diabetes of all types. The need for insulin depends upon the balance between insulin secretion and insulin resistance. All patients with type 1 diabetes need insulin treatment permanently, unless they receive an islet or whole organ pancreas transplant; many patients with type 2 diabetes will require insulin as their beta cell function declines over time.",
"   </p>",
"   <p>",
"    Indications for insulin therapy, available formulations of insulin, insulin pharmacokinetics, and determinants of efficacy will be reviewed here. The specifics of insulin therapy for type 1 and type 2 diabetes and intensive insulin therapy for critically ill patients who become hyperglycemic are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=see_link\">",
"     \"Insulin therapy in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=see_link\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WHICH PATIENTS NEED INSULIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin should be given to all patients with type 1 diabetes, which is due to autoimmune islet-cell injury that eventually leads to virtually complete insulin deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23210?source=see_link\">",
"     \"Pathogenesis of type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The peak incidence of type 1 diabetes is around the time of puberty, but about 25 percent of cases present after 35 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/1\">",
"     1",
"    </a>",
"    ]. Insulin is also indicated for patients with secondary diabetes due to pancreatic insufficiency, as well as in many patients with type 2 diabetes to manage hyperglycemia.",
"   </p>",
"   <p>",
"    Clinical features that, if present in a patient with diabetes at any age, suggest the need for insulin therapy include marked and otherwise unexplained recent weight loss (irrespective of the initial weight), a short history with severe symptoms, and the presence of moderate to heavy ketonuria. Diabetic ketoacidosis at first presentation usually indicates that the patient has type 1 diabetes and will require lifelong insulin treatment. However, some patients with type 2 diabetes, especially in the Afro-Caribbean populations (so-called \"Flatbush diabetes\") may present with ketoacidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=see_link\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32920?source=see_link\">",
"     \"Syndromes of ketosis-prone diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A more difficult question is when to use insulin in patients with type 2 diabetes. This disorder is characterized by both insulin resistance and relative insulin deficiency. Therapy should begin with diet, weight reduction, and exercise, which can frequently induce normoglycemia if compliance is optimal. Patients with persistent hyperglycemia are often started on one or more oral hypoglycemic drugs.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    is a good early choice, based on its safety profile, neutral effect with regard to weight gain, and ability to lower glycemia. Insulin is added if goal glycemic control is not attained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initiation of insulin therapy, however, is often unnecessarily delayed, owing to clinician or patient reluctance and other factors, thus exposing patients to the physiological consequences of prolonged hyperglycemia. Patients&rsquo; preconceptions about the use of insulin need to be addressed (",
"    <a class=\"graphic graphic_table graphicRef52039 \" href=\"UTD.htm?33/49/34588\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients should be made aware that initiating insulin does not represent a personal \"failure\" and that most patients with type 2 diabetes will eventually require exogenous insulin, due to decline in endogenous insulin production. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=see_link\">",
"     \"Insulin therapy in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INSULIN PREPARATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Human versus analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The time to peak and the duration of action of human insulin preparations (NPH [Neutral Protamine Hagedorn] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    ) do not replicate endogenous basal and postprandial insulin secretion. Thus, insulin analogs (lispro, aspart, glulisine, glargine, detemir, degludec) were developed. The very rapid-acting insulin analogs have both faster and shorter duration of action than regular insulin for pre-meal coverage, while the long-acting analogs have a longer and flatter profile than NPH for basal coverage.",
"   </p>",
"   <p>",
"    To produce an insulin preparation with a faster onset and shorter duration of action than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    , modifications were made in the insulin molecule to prevent it from forming hexamers or polymers that slow absorption and delay action [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10920?source=see_link\">",
"     insulin aspart",
"    </a>",
"    is identical to human regular insulin except for a substitution of aspartic acid for proline at position B28. This substitution results in a reduction in hexamer formation and consequently more rapid absorption, faster onset of action, and shorter duration of action [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/5\">",
"     5",
"    </a>",
"    ]. These rapid-acting insulin analogs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17160?source=see_link\">",
"     insulin lispro",
"    </a>",
"    , aspart, and glulisine) have an onset of action within 5 to 15 minutes, peak action at 45 to 75 minutes, and a duration of action of two to four hours (",
"    <a class=\"graphic graphic_table graphicRef73676 \" href=\"UTD.htm?1/62/2028\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/6-10\">",
"     6-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Different alterations result in the slower absorption and longer duration of action of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    , detemir, and degludec:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"       Insulin glargine",
"      </a>",
"      is identical to human insulin except for a substitution of glycine for asparagine in position A21 and by the addition of two arginine molecules in the B-chain of the insulin molecule [",
"      <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/11\">",
"       11",
"      </a>",
"      ]. These modifications result in a change in the pH such that, after subcutaneous administration, glargine precipitates in the tissue forming hexamers, which delays absorption and prolongs duration of action. Glargine has no appreciable peak and a duration of action that usually lasts 24 hours. Glargine cannot be mixed with rapid-acting insulins as the kinetics of both the glargine and rapid-acting insulin will be altered.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/49/25367?source=see_link\">",
"       Insulin detemir",
"      </a>",
"      is an acylated insulin; the fatty acid side chain allows albumin binding and results in prolongation of action. It is considerably less potent than human insulin and, therefore, it is formulated using a 4:1 molar ratio (ie, one detemir unit contains four times as many insulin detemir molecules as one unit of any other insulin). Compared with glargine, it does have a noticeable peak and rarely lasts 24 hours. Clinical trial results have suggested that twice per day injections may be necessary for optimal glycemic control. Detemir cannot be mixed with rapid-acting insulins as the kinetics of both the detemir and rapid-acting insulin will be altered.",
"     </li>",
"     <li>",
"      Insulin degludec is almost identical to human insulin, except for deletion of the last amino acid from the B-chain and the addition of a glutamyl link from LysB29 to a hexadecanedioic fatty acid [",
"      <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/12\">",
"       12",
"      </a>",
"      ]. This feature allows it to form soluble multihexamers at the injection site, from which monomers slowly separate and are absorbed. This property confers a long duration of action (&gt;40 hours) and reduces variability in plasma concentration with once daily dosing. In contrast to glargine and detemir insulins, degludec may be mixed with rapid-acting insulins without altering the kinetics of the degludec or the rapid-acting insulin. Insulin degludec is available in some countries, but not in the United States owing to concern regarding a potential increase in cardiovascular risk [",
"      <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;With respect to short-term outcomes, such as A1C and risk of hypoglycemia, the newer rapid-acting insulins may have a minor glycemic advantage over short-acting (regular) insulin in patients with type 1 diabetes, but not in patients with type 2 diabetes. The long-acting insulins, glargine and detemir, may have some modest clinical advantages over NPH (less symptomatic and nocturnal hypoglycemia) in type 2 diabetes, with the important disadvantage of higher cost. In type 1 diabetes,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    may have a slight glycemic advantage and detemir less risk of severe hypoglycemia compared with NPH. The trials examining these issues are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link&amp;anchor=H6#H6\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\", section on 'Multiple daily injections'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=see_link&amp;anchor=H6#H6\">",
"     \"Insulin therapy in type 2 diabetes mellitus\", section on 'Choice of insulin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is theoretical concern that changes in the structure of the insulin molecule (as occurs with the synthesis of insulin analogs) may inadvertently change other properties of insulin. As an example, glargine and detemir have different affinities (glargine higher, detemir lower) than human insulin for the insulin-like growth factor-1 (IGF-1) receptor, which theoretically could alter mitogenic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/4\">",
"     4",
"    </a>",
"    ]. An increase in mitogenic activity could increase the risk of some known diabetes complications, such as retinopathy, and could theoretically increase neoplastic transformation.",
"   </p>",
"   <p>",
"    There are few studies comparing insulin analogs and human insulin with respect to long-term outcomes, such as diabetic complications or mortality. In a retrospective review of four multinational trials of glargine versus NPH, more patients randomly assigned to glargine had an increase in three steps or more on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/14\">",
"     14",
"    </a>",
"    ]. However, the results from a randomized trial are more reassuring. In a five-year trial in over 1000 patients with type 2 diabetes previously treated with oral hypoglycemic agents, insulin, or both, there was no evidence of a greater risk of retinopathy progression (defined as three ETDRS steps or more) in patients randomly assigned to twice daily NPH versus once daily glargine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data regarding use of insulin analogs and risk of cancer are conflicting with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/16-23\">",
"     16-23",
"    </a>",
"    ]. Some retrospective population-based studies evaluating the risk of malignant neoplasms in patients with diabetes treated with human insulin or insulin analogs have raised a concern about a possible association between treatment with insulin glargine and an increased risk of cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. However, these studies have not consistently demonstrated increased risk. Moreover, those that have been positive do not prove causality and have several limitations, including a small number of cancer cases and important differences in the patient characteristics of those taking glargine alone versus other types of insulin, which may explain the increased risk.",
"   </p>",
"   <p>",
"    In a subsequent analysis of the manufacturer's pharmacovigilance database for all randomized clinical trials (10,880 patients) comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    with any comparator in type 1 or type 2 diabetes, there was no difference in the reported cases of malignancy between the insulin glargine and comparator groups (0.8 versus 0.9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/24\">",
"     24",
"    </a>",
"    ]. In a randomized trial comparing the addition of insulin glargine (to normalize fasting blood glucose) to standard care (only 11 percent treated with insulin) in patients with cardiovascular disease and either type 2 diabetes or prediabetes, there was no increase in cancer risk after 6.2 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Until more data are available, there is insufficient evidence to make a recommendation against glargine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/26\">",
"     26",
"    </a>",
"    ]. Insulin choices should continue to be individualized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=see_link\">",
"     \"Insulin therapy in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Basal versus bolus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin preparations can be divided into two basic categories based upon the duration of action:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intermediate- to long-acting preparations (NPH, Neutral Protamine Lispro [NPL], detemir, or glargine) are typically administered once or twice daily to provide basal insulin levels that suppress hepatic glucose production and maintain near normoglycemia in the fasting state. Intermediate-acting insulin (NPH) also provides some peak coverage for breakfast and lunch intake, although not as physiologic as replacement with faster-acting insulin given at mealtimes.",
"      <br/>",
"      <br/>",
"      Basal insulin levels can also be achieved by continuous infusion of a short or rapid-acting insulin via an insulin pump, used almost exclusively in type 1 diabetes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link&amp;anchor=H12#H12\">",
"       \"Insulin therapy in adults with type 1 diabetes mellitus\", section on 'Continuous subcutaneous insulin infusion (insulin pump)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Short-acting (regular) or rapid-acting (lispro, aspart, or glulisine) insulin are typically provided as a premeal bolus to cover the extra requirements after food is absorbed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The approximate time of onset, peak activity, and duration of action of the most commonly used insulins are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef73676 \" href=\"UTD.htm?1/62/2028\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The term \"conventional insulin therapy\" has been used to describe simpler insulin regimens, such as single daily injections, or two injections per day of regular and NPH insulin, mixed together in the same syringe and given in fixed amounts before breakfast and dinner. The term \"intensive insulin therapy\" is used to describe more complex regimens that separate basal insulin delivery (given as one to two daily injections of intermediate- or long-acting insulin) with superimposed doses of short-acting or rapid-acting insulins three or more times daily. While intensive regimens were initially used for patients with type 1 diabetes, they are now frequently used for patients with type 2 diabetes, as well. Conventional insulin therapy is unlikely to achieve target A1C levels in patients with type 1 diabetes, and may provide suboptimal glycemic control for patients with type 2 diabetes as beta cell function declines.",
"   </p>",
"   <p>",
"    Both glucose and insulin metabolism are altered in patients who have chronic renal failure. The changes in the insulin regimen that must be made in these patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7865?source=see_link\">",
"     \"Management of hyperglycemia in diabetics with end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8213208\">",
"    <span class=\"h2\">",
"     U-500 regular insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;U-500 is a concentrated form of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    that can be used to control hyperglycemia in severely insulin resistant patients. In several reports, U-500 insulin has been used successfully in patients with obesity, immune-mediated insulin resistance, and genetic abnormalities of the insulin receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/27\">",
"     27",
"    </a>",
"    ]. Because the high concentration of insulin delays absorption, the pharmacologic profile of U-500 regular insulin is most similar to that of NPH [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/28\">",
"     28",
"    </a>",
"    ]. In one observational study of 11 obese severely insulin-resistant, uncontrolled diabetic patients (requiring &gt;200 units of insulin daily), substituting U-500 regular insulin for U-100 NPH insulin improved diabetes control (mean A1C decrease from 9.9 to 7.1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/29\">",
"     29",
"    </a>",
"    ]. For patients who require over 300 units of insulin daily, the typical starting dose of U-500 regular insulin is 100 units (0.2 mL of U-500) twice daily. It is often dispensed using Tuberculin, rather than insulin, syringes to emphasize that it is different from U-100 regular insulin. With the Tuberculin syringe, every 0.1 mL is 50 units of insulin. Dose adjustments are made every two weeks based upon fasting and pre-dinner blood sugar measurements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Premixed insulins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of premixed insulins is not recommended for patients with type 1 diabetes, as intensive regimens require frequent adjustments of the premeal bolus of short-acting or rapid-acting insulin. Premixed",
"    <span class=\"nowrap\">",
"     Lispro/NPH",
"    </span>",
"    in type 1 diabetes may be of some benefit for patients who will not comply with an intensive regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients with type 2 diabetes who require premeal insulin in addition to basal insulin prefer premixed insulins for convenience. Some premixed (biphasic) insulin preparations are commercially available, but patients may also draw up their premeal and basal insulins in the same syringe prior to injection. However, there are problems with mixing different insulin preparations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When drawing up both insulin preparations in the same syringe, serum insulin concentrations tend to approach a single peak. This is less of a problem when a rapid-acting insulin rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"       regular insulin",
"      </a>",
"      is mixed with NPH and injected immediately after mixing [",
"      <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/31\">",
"       31",
"      </a>",
"      ]. It is also less of a problem with premixed insulins, such as Lispro Mix25 (25 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17160?source=see_link\">",
"       insulin lispro",
"      </a>",
"      and 75 percent of an intermediate-acting insulin) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The peak action also varies directly with the proportion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"       regular insulin",
"      </a>",
"      in the combination. One study, as an example, compared the time course of serum insulin concentrations with two mixtures of different NPH-to-regular insulin ratios:",
"      <span class=\"nowrap\">",
"       50/50",
"      </span>",
"      (equivalent to 10.5 units of each preparation in a 70 kg patient) and",
"      <span class=\"nowrap\">",
"       70/30",
"      </span>",
"      (equivalent to 14.7 units of NPH and 6.3 units of regular insulin) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/33\">",
"       33",
"      </a>",
"      ]. The former, which contained more regular insulin, resulted in higher serum insulin concentrations in the first six hours (",
"      <a class=\"graphic graphic_figure graphicRef57000 \" href=\"UTD.htm?35/32/36365\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Changes in the proportion of NPH-to-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"       regular insulin",
"      </a>",
"      in these premixed combinations are often not sufficient to improve postprandial glycemic control [",
"      <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/34\">",
"       34",
"      </a>",
"      ]. In addition, because of the variability in peak effect, it may be more difficult to achieve excellent glycemic control with premixed insulins even though they are easier to use [",
"      <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many patients with type 2 diabetes can use pre-mixed preparations with reasonable effect. However, if the aim is to truly vary the dose of fast-acting insulin before a meal, patients would do best to give the fast-acting and intermediate-acting insulins as separate injections. If near normoglycemia is the goal, it is preferable to keep basal and premeal insulin injections separate and to adjust them independently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     ADA guidelines for mixed-insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;We almost never recommend commercially premixed insulins in the treatment of type 1 diabetes. When commercially or self-mixed insulins are used for patients with type 2 diabetes, the following guidelines adapted from the American Diabetes Association (ADA) should be followed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are well-controlled on a self-mixed regimen should continue the same procedure for preparing their dose.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"       Insulin glargine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/49/25367?source=see_link\">",
"       insulin detemir",
"      </a>",
"      should not be mixed with other insulins due to the low pH of the diluents.",
"     </li>",
"     <li>",
"      After mixing NPH with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"       regular insulin",
"      </a>",
"      , the formulation should be used immediately.",
"     </li>",
"     <li>",
"      Rapid-acting insulin can be mixed with NPH. When this is done, the mixture should be injected within 15 minutes prior to a meal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Inhaled insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inhaled form of rapid-acting insulin was available for a short time but was discontinued in 2007. Other inhaled insulin preparations are in clinical trials but are not currently available. Studies have shown that inhaled insulin causes a very rapid rise in serum insulin concentration (similar to that after subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17160?source=see_link\">",
"     insulin lispro",
"    </a>",
"    and aspart, and faster than that after subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. However, due to its inefficient absorption, higher doses of insulin must be administered to achieve a therapeutic response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DETERMINANTS OF INSULIN EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective use of insulin requires an understanding of the major variables that affect the degree of glycemic control. These include the insulin preparation, the size of the subcutaneous depot, injection technique, the site of injection, and subcutaneous blood flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Type of insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The time of onset, peak activity, and duration of action of subcutaneous insulin preparations can only be approximated, since the usually quoted data are based upon the administration of small amounts of insulin to a few normal subjects (",
"    <a class=\"graphic graphic_table graphicRef73676 \" href=\"UTD.htm?1/62/2028\">",
"     table 2",
"    </a>",
"    ). Furthermore, the degree of absorption of any dose, both among patients and in the same patient, can vary from day to day by as much as 25 to 50 percent, leading to unexplained fluctuations in glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. This effect is greatest with longer-acting insulins and least with regular, lispro, aspart, and glulisine insulin. Thus, a dose of NPH insulin given before the evening meal may be sufficient to last through the night in one patient but may dissipate in another, resulting in fasting hyperglycemia. Part of the day-to-day variability in the absorption of NPH insulin may be due to incomplete mixing of the suspensions of insulin and protamine or zinc.",
"   </p>",
"   <p>",
"    The absorption of long-acting insulin analogs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    also seems to vary [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/41\">",
"     41",
"    </a>",
"    ]. In addition, there is some suggestion that the duration of action of detemir increases with higher doses [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Size of subcutaneous depot",
"    </span>",
"    &nbsp;&mdash;&nbsp;The variability in absorption is increased and net absorption is reduced with increasing size of the subcutaneous depot [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/39\">",
"     39",
"    </a>",
"    ]. This can become a limiting factor in patients who are insulin resistant and require large doses given several times per day. Conversely, one of the reasons why continuous subcutaneous insulin infusions may serve to smooth blood glucose control is that only regular or rapid-acting insulin is used and the size of the subcutaneous depot is very small (since the reservoir is held in a syringe or other chamber, outside the body) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another approach to reduce the size of the subcutaneous depot and thereby increase insulin absorption is to use high pressure jet injectors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/45\">",
"     45",
"    </a>",
"    ]. These devices lead to a more rapid fall in blood glucose concentrations and a shorter duration of insulin action [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/46\">",
"     46",
"    </a>",
"    ], although there is no evidence that the variability in insulin absorption is improved. Jet injectors may also cause less pain than traditional needles and syringes. However, they are expensive, difficult to maintain, and are not recommended for routine use.",
"   </p>",
"   <p>",
"    A variety of pen injectors, used with pre-filled cartridges, are now available and are more convenient than conventional syringes and bottles, but are more expensive. When small doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    (less than five units) are being given, the error in measuring the dose is almost 50 percent less when using pen injectors than with conventional insulin syringes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Injection technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injection technique is the same with insulin syringes and with pen injectors. Both the angle of needle entry and the depth of penetration affect the rate of insulin absorption. Very shallow insertion can cause a painful intradermal injection that is not well absorbed. In comparison, a perpendicular injection in a lean area may result in an intramuscular injection, from which absorption is more rapid [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should be referred to a certified diabetes educator to be taught proper insulin injection technique. The recommended technique is to use an area of the body in which about 2.5 cm (one inch) of subcutaneous fat can be pinched between two fingers. The syringe, with a 0.5 inch microfine (27G) or ultrafine (29G) needle, is inserted perpendicular to the pinched skin up to the hilt and the insulin is then injected. The syringe barrel should not be pulled back before injection or the needle removed if blood is obtained. The needle should be held in place for several seconds before being withdrawn [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/36\">",
"     36",
"    </a>",
"    ]. This is especially important when using pen injectors, to avoid insulin leakage after withdrawal of the needle.",
"   </p>",
"   <p>",
"    The common practice of cleaning the skin with an alcohol swab before injection may not be necessary. In a crossover study of 50 patients who received over 13,000 injections, there was no difference when the usual manner of injection was compared with injections through clothing [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/50\">",
"     50",
"    </a>",
"    ]. The only problem with the latter was an occasional blood stain on the clothing. Additional information on injection technique, mixing insulin, and syringe disposal is found elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Site of injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential sites for insulin injection are the upper arms, abdominal wall, upper legs, and buttocks (",
"    <a class=\"graphic graphic_figure graphicRef78710 \" href=\"UTD.htm?10/46/10981\">",
"     figure 2",
"    </a>",
"    ). A common cause of day-to-day variability in insulin action is the random rotation of injection sites from one region of the body to another. Insulin is absorbed fastest from the abdominal wall, slowest from the leg and buttock, and at an intermediate rate from the arm; at any of these sites, the rapidity of insulin absorption varies inversely with subcutaneous fat thickness [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/40,51\">",
"     40,51",
"    </a>",
"    ]. In a study using radiolabeled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    , the percent of the dose that disappeared at two hours was approximately 49 percent in the abdomen, 37 percent in the arm, and 26 percent in the leg [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/51\">",
"     51",
"    </a>",
"    ]. The postprandial rise in plasma glucose concentration varied inversely with the rate of insulin absorption, being 30 to 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.7 to 2.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    less after abdominal than after leg injection; the values after arm injection were intermediate between these responses.",
"   </p>",
"   <p>",
"    These differences can be useful clinically. Premeal regular or rapid-acting insulin should be rapidly absorbed, and injection into the abdominal wall may therefore be preferable. On the other hand, slower absorption from the leg or buttock may be desirable with the pre-evening meal dose of intermediate-acting insulin to ensure a duration of action that lasts through the night.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Alterations in subcutaneous blood flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of insulin absorption is also determined by the rate of subcutaneous blood flow. Thus, insulin absorption is reduced by smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/52\">",
"     52",
"    </a>",
"    ] and increased by any increases in skin temperature [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/53\">",
"     53",
"    </a>",
"    ] induced by exercise, saunas or hot baths, and local massage [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. These variations are more marked with regular and rapid-acting insulins than with longer-acting insulins [",
"    <a class=\"abstract\" href=\"UTD.htm?14/55/15225/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"       \"Patient information: Type 1 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"       \"Patient information: Type 2 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/58/28579?source=see_link\">",
"       \"Patient information: Using insulin (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/47/6899?source=see_link\">",
"       \"Patient information: Should I switch to an insulin pump? (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/28/18886?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insulin therapy is essential in all patients with type 1 diabetes, and is also often used in patients with type 2 diabetes. Although initial treatment for type 2 diabetes should be diet modification and exercise, followed by oral agents if normoglycemia is not achieved, insulin therapy is often indicated and its use should not be delayed when it becomes necessary. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Which patients need insulin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While intensive insulin therapy, utilizing a basal insulin with multiple premeal injections of a very rapidly acting insulin, has become standard therapy in type 1 diabetes, simpler regimens are often used in type 2 diabetes. The approximate time of onset, peak activity, and duration of action of the most commonly used insulins are shown in the table (",
"      <a class=\"graphic graphic_table graphicRef73676 \" href=\"UTD.htm?1/62/2028\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Insulin preparations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not prescribing premixed insulin for type 1 diabetes (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Premixed insulin may be considered in some patients with type 2 diabetes for convenience. Specific guidelines should be followed for premixing to avoid changes in speed of absorption and peak action. Commercially available premixed insulins are a reasonable choice if the insulin ratio is appropriate to the patient's insulin requirement. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Premixed insulins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Effective use of insulin requires an understanding of the major variables that affect the degree of glycemic control: the insulin preparation, the size of the subcutaneous depot, injection technique, the site of injection, and subcutaneous blood flow. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Determinants of insulin efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Insulin absorption is variable between patients and in the same patient, especially for longer acting preparations. Variability is greater with larger injection doses. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Size of subcutaneous depot'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Injections should be given into an area of pinched skin, with needle inserted perpendicular and up to the hilt; the barrel should not be pulled back. Precleaning skin with alcohol is unnecessary and may increase the pain of an injection. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Injection technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Absorption is fastest from injections into the abdominal wall, which may be a preferable site for premeal insulin. Slower absorption from the leg or buttock may be appropriate for evening doses of intermediate-acting insulin. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Site of injection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/1\">",
"      Harris MI, Robbins DC. Prevalence of adult-onset IDDM in the U.S. population. Diabetes Care 1994; 17:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/2\">",
"      Brunton S, Carmichael B, Funnell M, et al. Type 2 diabetes: the role of insulin. J Fam Pract 2005; 54:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/3\">",
"      Evans M, Schumm-Draeger PM, Vora J, King AB. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes Metab 2011; 13:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/4\">",
"      Zib I, Raskin P. Novel insulin analogues and its mitogenic potential. Diabetes Obes Metab 2006; 8:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/5\">",
"      Owen WE, Roberts WL. Cross-reactivity of three recombinant insulin analogs with five commercial insulin immunoassays. Clin Chem 2004; 50:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/6\">",
"      Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994; 43:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/7\">",
"      Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 1998; 21:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/8\">",
"      Hirsch IB. Insulin analogues. N Engl J Med 2005; 352:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/9\">",
"      Rapid acting insulin analogs. The Medical Letter 2009; 51:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/10\">",
"      Becker RH, Frick AD. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet 2008; 47:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/11\">",
"      Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/12\">",
"      Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012; 29:2104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/13\">",
"      Torjesen I. FDA raises concerns about ultra-long acting insulins given green light in Europe and Japan. BMJ 2012; 345:e7323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/14\">",
"      Davis MD, Beck RW, Home PD, et al. Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin. Exp Clin Endocrinol Diabetes 2007; 115:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/15\">",
"      Rosenstock J, Fonseca V, McGill JB, et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia 2009; 52:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/16\">",
"      Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/17\">",
"      Colhoun HM, SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009; 52:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/18\">",
"      Jonasson JM, Ljung R, Talb&auml;ck M, et al. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009; 52:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/19\">",
"      Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/20\">",
"      Rosenstock J, Fonseca V, McGill JB, et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 2009; 52:1971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/21\">",
"      Chang CH, Toh S, Lin JW, et al. Cancer risk associated with insulin glargine among adult type 2 diabetes patients--a nationwide cohort study. PLoS One 2011; 6:e21368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/22\">",
"      Morden NE, Liu SK, Smith J, et al. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care 2011; 34:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/23\">",
"      Suissa S, Azoulay L, Dell'Aniello S, et al. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 2011; 54:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/24\">",
"      Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009; 52:2499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/25\">",
"      ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367:319.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA Drug Safety Communication: Update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer. file://www.fda.gov/Drugs/DrugSafety/ucm239376.htm (Accessed on January 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/27\">",
"      Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care 2005; 28:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/28\">",
"      Ballani P, Tran MT, Navar MD, Davidson MB. Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients. Diabetes Care 2006; 29:2504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/29\">",
"      Davidson MB, Navar MD, Echeverry D, Duran P. U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients. Diabetes Care 2010; 33:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/30\">",
"      Roach P, Bai S, Charbonnel B, et al. Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus. Clin Ther 2004; 26:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/31\">",
"      Joseph SE, Korzon-Burakowska A, Woodworth JR, et al. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. Diabetes Care 1998; 21:2098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/32\">",
"      Koivisto VA, Tuominen JA, Ebeling P. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care 1999; 22:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/33\">",
"      Woodworth JR, Howey DC, Bowsher RR, et al. Comparative pharmacokinetics and glucodynamics of two human insulin mixtures. 70/30 and 50/50 insulin mixtures. Diabetes Care 1994; 17:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/34\">",
"      Brodows R, Chessor R. A comparison of premixed insulin preparations in elderly patients. Efficacy of 70/30 and 50/50 human insulin mixtures. Diabetes Care 1995; 18:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/35\">",
"      Dunbar JM, Madden PM, Gleeson DT, et al. Premixed insulin preparations in pen syringes maintain glycemic control and are preferred by patients. Diabetes Care 1994; 17:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/36\">",
"      American Diabetes Association. Insulin administration. Diabetes Care 2004; 27 Suppl 1:S106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/37\">",
"      Rave KM, Nosek L, de la Pe&ntilde;a A, et al. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care 2005; 28:2400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/38\">",
"      Brunner GA, Balent B, Ellmerer M, et al. Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients. Diabetologia 2001; 44:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/39\">",
"      Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care 1984; 7:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/40\">",
"      Sindelka G, Heinemann L, Berger M, et al. Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia 1994; 37:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/41\">",
"      Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000; 23:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/42\">",
"      Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005; 28:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/43\">",
"      Owens DR, Bolli GB. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther 2008; 10:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/44\">",
"      Lauritzen T, Pramming S, Deckert T, Binder C. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia 1983; 24:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/45\">",
"      Taylor R, Home PD, Alberti KG. Plasma free insulin profiles after administration of insulin by jet and conventional syringe injection. Diabetes Care 1981; 4:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/46\">",
"      Golden MP, Haymond M, Hinnen DA, et al. Position statement on jet injectors. Diabetes Care 1988; 11:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/47\">",
"      Lteif AN, Schwenk WF. Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care 1999; 22:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/48\">",
"      Galloway JA, Spradlin CT, Nelson RL, et al. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care 1981; 4:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/49\">",
"      Micossi P, Cristallo M, Librenti MC, et al. Free-insulin profiles after intraperitoneal, intramuscular, and subcutaneous insulin administration. Diabetes Care 1986; 9:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/50\">",
"      Fleming DR, Jacober SJ, Vandenberg MA, et al. The safety of injecting insulin through clothing. Diabetes Care 1997; 20:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/51\">",
"      Koivisto VA, Felig P. Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients. Ann Intern Med 1980; 92:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/52\">",
"      Klemp P, Staberg B, Madsbad S, K&oslash;lendorf K. Smoking reduces insulin absorption from subcutaneous tissue. Br Med J (Clin Res Ed) 1982; 284:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/53\">",
"      Riccio A, Avogaro A, Valerio A, et al. Improvement of basal hepatic glucose production and fasting hyperglycemia of type I diabetic patients treated with human recombinant ultralente insulin. Diabetes Care 1994; 17:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/54\">",
"      Koivisto VA, Felig P. Effects of leg exercise on insulin absorption in diabetic patients. N Engl J Med 1978; 298:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/55\">",
"      Koivisto VA. Sauna-induced acceleration in insulin absorption from subcutaneous injection site. Br Med J 1980; 280:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/56\">",
"      Linde B. Dissociation of insulin absorption and blood flow during massage of a subcutaneous injection site. Diabetes Care 1986; 9:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/55/15225/abstract/57\">",
"      Berger M, C&uuml;ppers HJ, Hegner H, et al. Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care 1982; 5:77.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1752 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-4C9EBFD82E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_55_15225=[""].join("\n");
var outline_f14_55_15225=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WHICH PATIENTS NEED INSULIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INSULIN PREPARATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Human versus analogs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Basal versus bolus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8213208\">",
"      U-500 regular insulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Premixed insulins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - ADA guidelines for mixed-insulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Inhaled insulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DETERMINANTS OF INSULIN EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Type of insulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Size of subcutaneous depot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Injection technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Site of injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Alterations in subcutaneous blood flow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1752\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1752|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/32/36365\" title=\"figure 1\">",
"      Efficacy of premixed insulins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/46/10981\" title=\"figure 2\">",
"      Insulin injection sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1752|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/49/34588\" title=\"table 1\">",
"      Resistance to insulin therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/62/2028\" title=\"table 2\">",
"      Insulin pharmacokinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=related_link\">",
"      Classification of diabetes mellitus and genetic diabetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=related_link\">",
"      Glycemic control and intensive insulin therapy in critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=related_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=related_link\">",
"      Insulin therapy in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/43/7865?source=related_link\">",
"      Management of hyperglycemia in diabetics with end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23210?source=related_link\">",
"      Pathogenesis of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/28/18886?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/47/6899?source=related_link\">",
"      Patient information: Should I switch to an insulin pump? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/58/28579?source=related_link\">",
"      Patient information: Using insulin (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32920?source=related_link\">",
"      Syndromes of ketosis-prone diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_55_15226="Immune globulin: Pediatric drug information";
var content_f14_55_15226=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Immune globulin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?1/23/1402?source=see_link\">",
"    see \"Immune globulin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/54/16230?source=see_link\">",
"    see \"Immune globulin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F15601262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Updates Immune Globulin Product Safety Information",
"     </span>",
"     <span class=\"collapsible-date\">",
"      November 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The Food and Drug Administration (FDA) has issued an updated Safety Communication regarding thrombotic events and hemolysis potentially associated with the administration of human immune globulin. Because thrombosis has previously been identified as a potential risk following human immune globulin administration, the agency continues to investigate whether specific characteristics of these products account for an increased risk. FDA scientists and product manufacturers have examined different lots of immune globulin products and found elevated levels of the activated clotting factor XIa in certain lots produced by different manufacturers. Higher levels of factor XIa were associated with a greater incidence of arterial and venous clot formation in patients receiving these products.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Acute intravascular hemolysis or delayed hemolytic anemia can also occur after immune globulin therapy. In some cases, this happens because immune globulins contain blood group antibodies that can act as hemolysins by coating red blood cells, causing a positive direct antibody (Coombs) test result and hemolysis. Isolated cases of hemolysis-related renal dysfunction/failure or disseminated intravascular coagulation have also been reported following treatment with immune globulins.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at",
"       <a href=\"file://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm327934.htm?source=govdelivery\" target=\"_blank\">",
"        file://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm327934.htm?source=govdelivery",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F11513229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F11513233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bivigam&trade;;",
"     </li>",
"     <li>",
"      Carimune&reg; NF;",
"     </li>",
"     <li>",
"      Flebogamma&reg; DIF;",
"     </li>",
"     <li>",
"      GamaSTAN&trade; S/D;",
"     </li>",
"     <li>",
"      Gammagard S/D&reg;;",
"     </li>",
"     <li>",
"      Gammagard&reg; Liquid;",
"     </li>",
"     <li>",
"      Gammaked&trade;;",
"     </li>",
"     <li>",
"      Gammaplex&reg;;",
"     </li>",
"     <li>",
"      Gamunex&reg;-C;",
"     </li>",
"     <li>",
"      Hizentra&reg;;",
"     </li>",
"     <li>",
"      Octagam&reg;;",
"     </li>",
"     <li>",
"      Privigen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11513234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Gamastan S/D;",
"     </li>",
"     <li>",
"      Gamimune&reg; N;",
"     </li>",
"     <li>",
"      Gammagard Liquid;",
"     </li>",
"     <li>",
"      Gammagard S/D;",
"     </li>",
"     <li>",
"      Gamunex&reg;;",
"     </li>",
"     <li>",
"      Hizentra&reg;;",
"     </li>",
"     <li>",
"      IGIVnex&reg;;",
"     </li>",
"     <li>",
"      Privigen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F13307640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Blood Product Derivative",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Immune Globulin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F13307724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Not all products are interchangeable with regards to route of administration; consult manufacturers' labeling for additional information. Consider osmolarity and concentration during product selection; infuse as slowly as indication and stability allow (see \"Immune Globulin Product Comparison\" section in Appendix for details).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Immune (idiopathic) thrombocytopenic purpura (ITP):",
"     </b>",
"     I.V.: 400-1000 mg/kg/day for 2-5 consecutive days (total dose: 2000 mg/kg); maintenance dose: 400-1000 mg/kg/dose every 3-6 weeks based on clinical response and platelet count",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Isoimmune hemolytic disease (Rh-incompatibility):",
"     </b>",
"     I.V.: GA &ge;35 weeks: 500-1000 mg/kg/dose once over 2 hours; if needed, dose may be repeated in 12 hours; most effective when administered as soon as possible after diagnosis (AAP Subcommittee on Hyperbilirubinemia, 2004; Girish, 2008; Gottstein, 2003; Miqdad, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Myasthenia gravis (severe exacerbation):",
"     </b>",
"     I.V.: 400-1000 mg/kg/dose once daily over 2-5 days for a total dose of 2000 mg/kg; if additional therapy required, dose should be based on clinical response and titrated  to minimum effective dose (Bassan, 1998; Feasby, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Myocarditis, acute:",
"     </b>",
"     I.V.: 2000 mg/kg as a single dose. A cohort study of 21 young patients, including neonates, showed improvement in LVF recovery and survival at 1 year as compared to untreated historical cohort (Drucker, 1994); efficacy results are variable (English, 2004; Hia, 2004; Klugman, 2010); the largest data analysis did not show clear clinical benefit nor positive impact on survival; further studies are needed (Klugman, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Sepsis, adjunctive treatment:",
"     </b>",
"     I.V.: Limited data available; efficacy results variable: Usual dose: 500-1000 mg/kg/dose once daily for 1-3 days (Jenson, 1997; Ohlsson, 2010). The largest trial, INIS (n=3493), reported no difference in outcomes (including incidence of subsequent sepsis, death, or major disability at 2 years) between treatment and control groups using 500 mg/kg/day for 2 days (INIS Collaborative Group, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F13307648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/23/1402?source=see_link\">",
"      see \"Immune globulin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Not all products are interchangeable with regards to route of administration; consult manufacturers' labeling for additional information. Product-specific dosing provided where applicable; some clinicians use ideal body weight or an adjusted ideal body weight in morbidly-obese patients to calculate an IVIG dose (Siegel, 2010, Wimperis, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, Adolescents, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Acute disseminated encephalomyelitis (ADEM)",
"     </b>",
"     (Feasby, 2007): I.V.: Children: 1000 mg/kg/dose once daily for 2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      B-cell chronic lymphocytic leukemia (CLL):",
"     </b>",
"     I.V.: Gammagard S/D&reg;: 400 mg/kg/dose every 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Chronic inflammatory demyelinating polyneuropathy (CIDP):",
"     </b>",
"     I.V.: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     General dosing (Feasby, 2007): Initial: 400-1000 mg/kg/dose once daily for 2-5 days for a total dose of 2000 mg/kg; if maintenance therapy required dose and frequency should be based on clinical response and should not exceed 2000 mg/kg per treatment course",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Gamunex&reg;-C, Gammaked&trade;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Initial: 400-1000 mg/kg/dose once daily for 2-5 days for a total dose of 2000 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Maintenance therapy: 500-1000 mg/kg/dose for 1-2 days for a total dose of 1000 mg/kg every 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Colitis due to",
"      <i>",
"       Clostridium difficile",
"      </i>",
"      , chronic:",
"     </b>",
"     I.V.: Limited data available: Infants and Children: 400 mg/kg/dose every 3 weeks resulted in resolution of colitis symptoms during treatment; duration of therapy was unclear (n=5; age range: 6-37 months) (Abougergi, 2011; Leung, 1991; McFarland, 2000;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009); further studies are needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Dermatomyositis, refractory",
"     </b>",
"     (Feasby, 2007): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children: 1000 mg/kg/dose once daily for 2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: 400-1000 mg/kg/dose once daily over 2-5 days for a total dose of 2000 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     If maintenance therapy is required, the dose and frequency should be based on clinical response and doses should not exceed 2000 mg/kg per treatment course.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Guillain-Barr&eacute; syndrome:",
"     </b>",
"     I.V.: Various regimens have been used:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children: 1000 mg/kg/dose once daily for 2 days (Feasby, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: 400-1000 mg/kg/dose once daily over 2-5 days for a total cumulative dose of 2000 mg/kg (Feasby, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hematopoietic cell transplantation (HCT) with hypogammaglobulinemia (IgG &lt;400 mg/dL), prevention of bacterial infection",
"     </b>",
"     (Tomblyn, 2009): I.V.:",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:8em;\">",
"     Within first 100 days after HCT:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children (Allogeneic HCT recipients): 400 mg/kg/dose once monthly; increase dose or frequency to maintain IgG concentration &gt;400 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents and Adults: 500 mg/kg/dose once weekly; increase dose or frequency to maintain IgG concentration &gt;400 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;100 days after HCT: Children, Adolescents and Adults: 500 mg/kg/dose every 3-4 weeks; increase dose or frequency to maintain IgG concentration &gt;400 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hepatitis A, prophylaxis: Note:",
"     </b>",
"     Hepatitis A vaccine preferred for patients 12 months to 40 years (CDC, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.M.: GamaSTAN&trade; S/D:",
"     <b>",
"      Note:",
"     </b>",
"     In adults, injections &gt;10 mL should be split into multiple injections given at different sites; in pediatric patients, consider splitting doses &lt;10 mL based on patient size",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Pre-exposure prophylaxis upon travel into endemic areas:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Anticipated duration of risk &lt;3 months: 0.02",
"     <b>",
"      mL",
"     </b>",
"     /kg/dose as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Anticipated duration of risk &ge;3 months: 0.06",
"     <b>",
"      mL",
"     </b>",
"     /kg/dose once every 4-6 months if exposure continues",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Postexposure prophylaxis: 0.02",
"     <b>",
"      mL",
"     </b>",
"     /kg/dose as a single dose given within 14 days of exposure and/or prior to manifestation of disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      HIV infection, pediatric",
"     </b>",
"     (CDC, 2009): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Primary prophylaxis for serious bacterial infection in patients with hypogammaglobulinemia (IgG &lt;400 mg/dL): 400 mg/kg/dose every 2-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Secondary prophylaxis for invasive bacterial infections: Should only be used if subsequent infections are severe or frequent (&gt;2 infections during a 1-year period): 400 mg/kg/dose every 2-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Immune (idiopathic) thrombocytopenic purpura (ITP):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     General dosing:",
"     <b>",
"      Note:",
"     </b>",
"     Dosing regimens variable, consult product specific information if available:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Acute therapy: 400-1000 mg/kg/dose once daily for 2-5 consecutive days for a total cumulative dose of 2000 mg/kg; in some cases, cumulative doses up to 3000 mg/kg have been used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Chronic therapy: 400-1000 mg/kg/dose every 3-6 weeks based on clinical response and platelet count",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Carimune&reg; NF:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Acute therapy: 400 mg/kg/dose once daily for 2-5 days to maintain platelet count &ge;30,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and/or to control significant bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Chronic therapy: 400 mg/kg/dose as a single infusion; may increase to 800-1000 mg/kg/dose to maintain platelet count &ge;30,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and/or to control significant bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Gammagard S/D&reg;: Acute or chronic therapy: 1000 mg/kg/dose on alternate days for up to 3 doses based on patient response and/or platelet count",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Gammaked&trade;: 400-1000 mg/kg/dose once daily for 2-5 consecutive days for a total cumulative dose of 2000 mg/kg; if an adequate platelet response is observed after the initial 1000 mg/kg/dose, then the subsequent dose may be held",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Gamunex-C&reg;: Acute or chronic therapy: 1000 mg/kg/dose once daily for 1-2 days based on patient response and/or platelet response",
"     <b>",
"      or",
"     </b>",
"     for fluid-restricted patients or other conditions sensitive to volume: 400 mg/kg once daily for 5  days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Privigen&reg;: Chronic therapy: 1000 mg/kg/dose once daily for 2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Immunoglobulin deficiency",
"     </b>",
"     I.M.: GamaSTAN&trade; S/D:",
"     <b>",
"      Note:",
"     </b>",
"     In adults, injections &gt;10 mL should be split into multiple injections given at different sites; in pediatric patients, consider splitting doses &lt;10 mL based on patient size.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Initial: 1.32",
"     <b>",
"      mL",
"     </b>",
"     /kg/dose as a single dose, followed by maintenance dose in 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance: 0.66",
"     <b>",
"      mL",
"     </b>",
"     /kg/dose every 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Kawasaki disease:",
"     </b>",
"     I.V.: 2000 mg/kg as a single dose within 10 days of disease onset; must be used in combination with aspirin; if signs and symptoms persist &ge;36 hours after completion of the infusion, retreatment with a second 2000 mg/kg infusion should be considered (Newburger, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Measles, prophylaxis in patient with primary humoral immunodeficiency:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Pre-exposure (eg, during an outbreak, travel to endemic area):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     I.V. (Gamunex&reg;-C, Octagam&reg;): &ge;400 mg/kg/dose immediately before expected exposure;",
"     <b>",
"      Note:",
"     </b>",
"     Should only administer in patients whose routine dose is &lt;400 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     SubQ infusion (Hizentra&reg;): Children, Adolescents, and Adults: &ge;200 mg/kg/dose once weekly for 2 consecutive weeks for patients at risk of measles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Postexposure:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     I.V. (Gamunex&reg;-C, Octagam&reg;): 400 mg/kg/dose administered as soon as possible after exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     I.M. (GamaSTAN&trade; S/D): 0.25",
"     <b>",
"      mL",
"     </b>",
"     /kg/dose as a single dose given within 6 days of exposure; dose may be increased to 0.5",
"     <b>",
"      mL",
"     </b>",
"     /kg/dose in immunocompromised patients; maximum dose: 15 mL (Watson, 1998);",
"     <b>",
"      Note:",
"     </b>",
"     In adults, injections &gt;10 mL should be split into multiple injections given at different sites; in pediatric patients, consider splitting doses &lt;10 mL based on patient size",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     SubQ infusion (Hizentra&reg;): Children, Adolescents, and Adults: 200 mg/kg/dose as soon as possible following exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Multiple sclerosis (relapsing-remitting, when other therapies cannot be used):",
"     </b>",
"     I.V.: Dosage regimen variable; optimal dose not established: 1000 mg/kg/dose once monthly, with or without an induction of 400 mg/kg/day for 5 days (Feasby, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Myasthenia gravis (Juvenile and Adult, severe exacerbation):",
"     </b>",
"     I.V.: 400-1000 mg/kg/dose once daily over 2-5 days for a total dose of 2000 mg/kg; if additional therapy required, dose should be based on clinical response and titrated  to minimum effective dose (Feasby, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Myocarditis, acute:",
"     </b>",
"     I.V.: Infants and Children: 2000 mg/kg as a single dose. A cohort study of 21 children showed improvement in LVF recovery and survival at 1 year as compared to untreated historical cohort (Drucker, 1994); efficacy results are variable (English, 2004; Hia, 2004; Klugman, 2010); the largest data analysis did not show clear clinical benefit nor positive impact on survival; further studies are needed (Klugman, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Polymyositis, refractory",
"     </b>",
"     (Feasby, 2007): I.V.: Adults: 400-1000 mg/kg/dose once daily over 2-5 days for a total dose of 2000 mg/kg per treatment course. If maintenance therapy is required, the dose and frequency should be based on clinical response and doses should not exceed 2000 mg/kg per treatment course.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Primary immunodeficiency disorders:",
"     </b>",
"     Adjust dose/frequency based on desired IgG concentration and clinical response; maintain a trough IgG concentration of 500 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: General dosing: 200-800 mg/kg/dose every 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Carimune&reg; NF: 400-800 mg/kg/dose every 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Flebogamma&reg; DIF, Gammagard&reg; Liquid, Gammagard S/D&reg;, Gammaked&trade;, Gamunex&reg;-C, Octagam&reg;: 300-600 mg/kg/dose every 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Gammaplex&reg;: 300-800 mg/kg/dose every 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     SubQ infusion: Children, Adolescents, and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Begin 1 week after last I.V. dose and then administer weekly; for Hizentra&reg;, it is recommended that patients receive 3 months of I.V. immune globulin before initiating SubQ infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Gammagard&reg; Liquid, Gammaked&trade;, Gamunex&reg;-C: Initial weekly dose: Dose (grams) = [1.37 x I.V. dose (grams)] divided by [I.V. dose interval (weeks)]; Subsequent doses: Refer to product labeling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Hizentra&reg;: Initial weekly dose: Dose (grams) = [1.53 x I.V. dose (grams)] divided by [I.V. dose interval (weeks)]; Subsequent doses: Refer to product labeling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Rubella, prophylaxis during pregnancy:",
"     </b>",
"     I.M.: GamaSTAN&trade; S/D: Postexposure: 0.55",
"     <b>",
"      mL",
"     </b>",
"     /kg/dose as a single dose within 72 hours of exposure (Watson, 1998);",
"     <b>",
"      Note:",
"     </b>",
"     In adults, injections &gt;10 mL should be split into multiple injections given at different sites; in pediatric patients, consider splitting doses &lt;10 mL based on patient size",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Stevens-Johnson syndrome (SJS)/ toxic epidermal necrolysis (TEN):",
"     </b>",
"     I.V.: Infants, Children, and Adolescents: Limited data available: Usual dose: 1500-2000 mg/kg total dose as a single dose or divided over 2-4 days; dosing based on retrospective reviews and case reports; efficacy results are variable, further studies needed (Koh, 2010; Morci 2000; Tristani-Firouzi, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Varicella-zoster, postexposure prophylaxis (independent of HIV-status): Note:",
"     </b>",
"     Use only if varicella-zoster immune globulin is unavailable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.V.: 400 mg/kg as a single infusion within 96 hours of exposure (CDC, 2009;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     I.M. (GamaSTAN&trade; S/D): 0.6-1.2",
"     <b>",
"      mL",
"     </b>",
"     /kg/dose as a single dose within 72 hours of exposure;",
"     <b>",
"      Note:",
"     </b>",
"     In adults, injections &gt;10 mL should be split into multiple injections given at different sites; in pediatric patients, consider splitting doses &lt;10 mL based on patient size",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F11513299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carimune&reg; NF: 3 g, 6 g, 12 g [contains sucrose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gammagard S/D&reg;: 2.5 g [DSC] [contains albumin (human), glucose, glycine, natural rubber/natural latex in packaging, polyethylene glycol, polysorbate 80; IgA &lt;2.2 mcg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gammagard S/D&reg;: 5 g [contains albumin (human), glucose, glycine, natural rubber/natural latex in packaging, polyethylene glycol, polysorbate 80; IgA &lt;1 mcg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gammagard S/D&reg;: 5 g [DSC] [contains albumin (human), glucose, glycine, natural rubber/natural latex in packaging, polyethylene glycol, polysorbate 80; IgA &lt;2.2 mcg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gammagard S/D&reg;: 10 g [contains albumin (human), glucose, glycine, natural rubber/natural latex in packaging, polyethylene glycol, polysorbate 80; IgA &lt;1 mcg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gammagard S/D&reg;: 10 g [DSC] [contains albumin (human), glucose, glycine, natural rubber/natural latex in packaging, polyethylene glycol, polysorbate 80; IgA &lt;2.2 mcg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bivigam&trade;: 10% [100 mg/mL] (50 mL, 100 mL) [sucrose free; contains glycine, polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flebogamma&reg; DIF: 5% [50 mg/mL] (10 mL, 50 mL, 100 mL, 200 mL, 400 mL); 10% [100 mg/mL] (100 mL, 200 mL) [contains polyethylene glycol, sorbitol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GamaSTAN&trade; S/D: 15% to 18% [150 to 180 mg/mL] (2 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gammagard&reg; Liquid: 10% [100 mg/mL] (10 mL, 25 mL, 50 mL, 100 mL, 200 mL, 300 mL) [sucrose free; contains glycine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gammaked&trade;: 10% [100 mg/mL] (10 mL, 25 mL, 50 mL, 100 mL, 200 mL) [sucrose free; contains glycine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gammaplex&reg;: 5% [50 mg/mL] (50 mL, 100 mL, 200 mL) [sucrose free; contains glycine, natural rubber/natural latex in packaging, polysorbate 80, sorbitol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gamunex&reg;-C: 10% [100 mg/mL] (10 mL, 25 mL, 50 mL, 100 mL, 200 mL) [contains glycine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hizentra&reg;: 20% [200 mg/mL] (5 mL, 10 mL, 20 mL) [contains L-proline, polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Octagam&reg;: 5% [50 mg/mL] (20 mL, 50 mL, 100 mL, 200 mL) [sucrose free; contains maltose, sodium 30 mmol/L]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Privigen&reg;: 10% [100 mg/mL] (50 mL, 100 mL, 200 mL) [sucrose free; contains L-proline]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F11513236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F15841018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bivigam&trade;: FDA approved December 2012; anticipated availability is currently undetermined. Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13307649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     If plasmapheresis employed for treatment of condition, administer immune globulin",
"     <b>",
"      after",
"     </b>",
"     completion of plasmapheresis session.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: For initial treatment, a lower concentration and/or a slower rate of infusion should be used. Initial and maximum infusion rates are product-specific; Initial: 0.3-0.6 mL/kg/hour; if tolerated, the infusion rate may be increased every 30 minutes in a stepwise approach until maximum infusion rate is achieved; maximum: 4-8 mL/kg/hour; refer to manufacturers&rsquo; labeling for specific information. Administer in separate infusion line from other medications; if using primary line, flush with NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W (product specific; refer to manufacturer's labeling). Refrigerated product should be warmed to room temperature prior to infusion. Some products require filtration; refer to  manufacturer&rsquo;s labeling. Antecubital veins should be used, especially with concentrations &ge;10% to prevent injection site discomfort. Decrease dose, rate, and/or concentration of infusion in patients who may be at risk of renal impairment or thrombosis. Decreasing the rate or stopping the infusion may help relieve some adverse effects (flushing, changes in pulse rate, changes in blood pressure). Epinephrine should be available during administration. See Immune Globulin Product Comparison for more information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.: Administer I.M. in the anterolateral aspects of the upper thigh or deltoid muscle of the upper arm. Avoid gluteal region due to risk of injury to sciatic nerve. Divide doses &gt;10 mL (adult) and inject in multiple sites; in pediatric patients, consider splitting doses &lt;10 mL based on patient size.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SubQ infusion: Initial dose should be administered in a healthcare setting capable of providing monitoring and treatment in the event of hypersensitivity. Using aseptic technique, follow the infusion device manufacturer&rsquo;s instructions for filling the reservoir and preparing the pump. Remove air from administration set and needle by priming. Appropriate injection sites include the abdomen, thigh, upper arm, and/or lateral hip; dose may be infused into multiple sites (spaced &ge;2 inches apart) simultaneously. After administration sites are clean and dry, attach infusion device (eg, primed needle and administration set); ensure blood vessel has not been inadvertently accessed; if blood is present, remove and discard needle and tubing; repeat process using a new needle and tubing and different injection site. Repeat for each administration site; deliver the dose following instructions for the infusion device. Rotate the site(s) weekly. Treatment may be transitioned to the home/home care setting in the absence of adverse reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gammagard&reg; Liquid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Injection sites: &lt;8 simultaneous injection sites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Recommended infusion rate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &lt;40 kg (&lt; 88 lbs): Initial infusion: 15 mL/hour per injection site; subsequent infusions: 15-20 mL/hour per injection site; maximum: 160 mL/hour for all simultaneous sites combined",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &gt;40 kg (&gt;88 lbs): Initial infusion: 20 mL/hour per injection site; subsequent infusions: 20-30 mL/hour per injection site; maximum: 240 mL/hour for all simultaneous sites combined",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maximum infusion volume:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &lt;40 kg (&lt; 88 lbs): 20 mL per injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &gt;40 kg (&gt; 88 lbs): 30 mL per injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gammaked&trade;, Gamunex&reg;-C:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Injection sites: &le;8 simultaneous injection sites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Recommended infusion rate: 20 mL/hour per injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hizentra&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Injection sites: &le;4 simultaneous injection sites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maximum infusion rate: First infusion: 15 mL/hour per injection site; subsequent infusions: 25 mL/hour per injection site; maximum: 50 mL/hour for all simultaneous sites combined",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maximum infusion volume: First 4 infusions: 15 mL per injection site; subsequent infusions: 20 mL per injection site; maximum: 25 mL per site as tolerated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Carimune&reg; NF: pH 6.4-6.8",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Flebogamma&reg; DIF: pH 5.0-6.0",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     GamaSTAN&trade; S/D: pH 6.4-7.2",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gammagard&reg; Liquid: pH 4.6-5.1",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gammagard S/D&reg; 5%: pH 6.4-7.2",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gammaked&trade;: 4.0-4.5",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gammaplex&reg;: pH 4.8-5.0",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gamunex-C&reg;: pH 4.0-4.5",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hizentra&reg;: pH: 4.6-5.2",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Octagam&reg;: pH 5.1-6.0",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Privigen&reg;: pH 4.6-5.0",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F11513264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable (variable/product dependent) in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      15",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Fluconazole, sargramostim.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F13307645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stability and dilution information are product-specific. Do not freeze. Gently swirl; do not shake; avoid foaming. Discard unused portion of vials. Do not mix products from different manufacturers or with other drugs or I.V. infusion fluids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carimune&reg; NF: Prior to reconstitution, store at &le;30&deg;C (86&deg;F). Reconstitute with NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, or SWI. Following reconstitution; store under refrigeration. Begin infusion within 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flebogamma&reg; DIF: Store at 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F). Dilution is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GamaSTAN&trade; S/D: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gammagard&reg; Liquid: Prior to use, store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for up to 36 months; may store at room temperature of 25&deg;C (77&deg;F) for 12 months within the first 24 months of manufacturing. Dilute only with D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gammagard S/D&reg;: Store at &le;25&deg;C (&le;77&deg;F). Reconstitute with SWI; store reconstituted solution under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for up to 24 hours if originally prepared in a sterile laminar air flow environment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gammaked&trade;: May be stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for up to 36 months or at &le;25&deg;C (&le;77&deg;F) for up to 6 months. Dilute only with D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gammaplex&reg;: Store at 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F); protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gamunex&reg;-C: May be stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for up to 36 months or at &le;25&deg;C (&le;77&deg;F) for up to 6 months. Dilute only with D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hizentra&reg;: Store at &le;25&deg;C (&le;77&deg;F); protect from light",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Octagam&reg;: Store at 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Privigen&reg;: Store at &le;25&deg;C (&le;77&deg;F); protect from light. If further dilution required, D",
"     <sub>",
"      5",
"     </sub>",
"     W may be used.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13307641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of primary humoral immunodeficiency syndromes [may include but not limited to: Congenital agammaglobulinemia, severe combined immunodeficiency syndromes (SCIDS), common variable immunodeficiency, X-linked immunodeficiency, Wiskott-Aldrich syndrome]; acute and chronic immune (idiopathic) thrombocytopenic purpura (ITP); and chronic inflammatory demyelinating polyneuropathy (CIDP). Prevention of coronary artery aneurysms associated with Kawasaki syndrome (in combination with aspirin).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Adjunctive treatment of bacterial infection in patients with hypogammaglobulinemia and/or recurrent bacterial infections with B-cell chronic lymphocytic leukemia (CLL); and serious infection in immunoglobulin deficiency (select agammaglobulinemias).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     To provide passive immunity for prophylaxis in the following susceptible individuals:  Hepatitis A [pre-exposure and postexposure (within 14 days and/or prior to manifestation of disease)]; measles [postexposure (within 6 days) in an unvaccinated or nonimmune person];  rubella [postexposure (within 72 hours) during early pregnancy]; and varicella zoster (immunosuppressed patients when varicella zoster immune globulin is unavailable).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     See table for product specific indications, FDA approved age ranges, and routes of administration.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <col align=\"center\" width=\"125\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Product",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Indication",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         FDA Approval Ages",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Route(s)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Carimune&reg; NF",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Primary immunodeficiency (treatment)",
"        </p>",
"       </td>",
"       <td align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Pediatric patients (age not specified) and adults",
"        </p>",
"       </td>",
"       <td align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Intravenous",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Acute and chronic ITP (treatment)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Flebogamma&reg; 5% DIF",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Primary immunodeficiency (treatment)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Adults",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Intravenous",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Flebogamma&reg; 10% DIF",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Primary immunodeficiency (treatment)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Adults",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Intravenous",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" rowspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         GamaSTAN&trade; S/D",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Passive immunity - Hepatitis A",
"        </p>",
"       </td>",
"       <td align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Pediatric patients (age not specified) and adults",
"        </p>",
"       </td>",
"       <td align=\"center\" rowspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         Intramuscular",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Passive immunity - Measles",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Passive immunity - Rubella",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Adults",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Passive immunity - Varicella",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Pediatric patients (age not specified) and adults",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Serious infection in immunoglobulin deficiency (prevention)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Adults",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Gammagard&reg; Liquid",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Primary immunodeficiency (treatment)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-16 years and adults",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Intravenous, Subcutaneous",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" rowspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         Gammagard S/D&reg;",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Primary immunodeficiency (treatment)",
"        </p>",
"       </td>",
"       <td align=\"center\" rowspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         Pediatric patients (age not specified) and adults",
"        </p>",
"       </td>",
"       <td align=\"center\" rowspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         Intravenous",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         B-cell chronic lymphocytic leukemia (CLL)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Acute and chronic ITP (treatment)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Kawasaki syndrome",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" rowspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         Gammaked&trade;",
"        </p>",
"       </td>",
"       <td align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Primary immunodeficiency (treatment)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0-16 years and adults",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Intravenous",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Adults",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Subcutaneous",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Acute ITP (treatment)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Pediatric patients (age not specified) and adults",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Intravenous",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Chronic inflammatory demyelinating polyneuropathy (CIDP)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Adults",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Intravenous",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Gammaplex&reg;",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Primary immunodeficiency (treatment)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Pediatric patients (age not specified) and adults",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Intravenous",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" rowspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         Gamunex&reg;-C",
"        </p>",
"       </td>",
"       <td align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Primary immunodeficiency (treatment)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0-16 years and adults",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Intravenous",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Adults",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Subcutaneous",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Acute and chronic ITP (treatment)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Pediatric patients (age not specified) and adults",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Intravenous",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Chronic inflammatory demyelinating polyneuropathy (CIDP)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Adults",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Intravenous",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Hizentra&reg;",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Primary immunodeficiency (treatment)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;2 years and adults",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Subcutaneous",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Octagam&reg;",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Primary immunodeficiency (treatment)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6-16 years and adults",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Intravenous",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Privigen&reg;",
"        </p>",
"       </td>",
"       <td align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Primary immunodeficiency (treatment)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;3 years and adults",
"        </p>",
"       </td>",
"       <td align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Intravenous",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;15 years and adults",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Has also been used for acute myocarditis, Guillain-Barr&eacute; syndrome, hematopoietic stem cell transplantation with hypogammaglobulinemia, isoimmune hemolytic disease (Rh-incompatibility), neonatal sepsis, pediatric HIV infection and associated thrombocytopenia, refractory dermatomyositis, Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), and refractory polymyositis.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F11513231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Gamimune&reg; N may be confused with CytoGam&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Immune globulin (intravenous) may be confused with hepatitis B immune globulin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F11513251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angioedema, chest tightness, edema, flushing of the face, hyper-/hypotension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, aseptic meningitis syndrome, chills, dizziness, drowsiness, fatigue, fever, headache, irritability, lethargy, lightheadedness, malaise, migraine, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Bruising, contact dermatitis, eczema, erythema, hyperhidrosis, petechiae, pruritus, purpura, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration, hyperglycemia (neuromuscular disease)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, abdominal pain, anorexia (neuromuscular disease), diarrhea, discomfort, dyspepsia, gastroenteritis, nausea, sore throat, toothache, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, autoimmune hemolytic anemia, hematocrit decreased, hematoma, hemolysis (mild), hemorrhage, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Bilirubin increased, LDH increased, liver function test increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Muscle stiffness at I.M. site; pain, swelling, redness or irritation at the infusion site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back or hip pain, leg cramps, muscle cramps, myalgia, muscle spasm, neck pain, rigors, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Ear pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute renal failure, acute tubular necrosis, anuria, BUN increased, creatinine increased, oliguria, proximal tubular nephropathy, osmotic nephrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma aggravated, bronchitis, cough, dyspnea, epistaxis, nasal congestion, oropharyngeal pain, pharyngeal pain, pharyngitis, rhinitis, rhinorrhea, sinus headache, sinusitis, upper respiratory infection, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, flu-like syndrome, hypersensitivity reactions, infusion reaction, thermal burn",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Apnea, ARDS, autoimmune pure red cell aplasia (PRCA) exacerbation, bronchopneumonia, bullous dermatitis, cardiac arrest, coma, Coombs' test positive, cyanosis, epidermolysis, erythema multiforme, heart failure, hepatic dysfunction, hypoxemia, leukopenia, loss of consciousness, MI, pancytopenia, phlebitis, pulmonary edema, pulmonary embolism, seizures, Stevens-Johnson syndrome, stroke, thromboembolism, transfusion-related acute lung injury (TRALI), vascular collapse",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13307642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to immune globulin, corn (Octagam&reg;), or any component;  IgA deficiency especially if anti-IgA antibodies are present and/or there is a history of  hypersensitivity (except with the use of Gammagard&reg; S/D or GamaSTAN&trade; S/D; these agents are contraindicated in selective/isolated IgA deficiency where IgA deficiency is the only abnormality of concern);   hyperprolinemia (Hizentra&reg;, Privigen&reg;); severe thrombocytopenia or coagulation disorders where IM injections are contraindicated; do not administer as SubQ infusion in patients with ITP due to the risk of hematoma formation.",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13307672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not all products are interchangeable; consult manufacturer&rsquo;s labeling for additional information related to route of administration. Use with caution in patients with a history of cardiovascular disease or thrombotic episodes. Rapid IVIG infusion may be a possible risk factor for vascular occlusive events associated with IVIG. Do not exceed manufacturer's recommended initial infusion rate, use a lower IVIG concentration, and advance slowly in patients at risk. Monitor for adverse events during and after the infusion. Discontinue administration with signs of infusion reaction (fever, chills, nausea, vomiting, and rarely shock). Risk of adverse events may be increased with initial treatment, when switching brands of immune globulin, and with treatment interruptions of &gt;8 weeks. Assure that patients are not volume depleted prior to the initiation of an IVIG infusion.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in IgA deficiency; an increased risk of hypersensitivity, especially in patients with anti-IgA antibodies present.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Some clinicians may administer intravenous immune globulin products as a subcutaneous infusion based on patient tolerability and clinical judgment. SubQ infusion should begin 1 week after the last I.V. dose; dose should be individualized based on clinical response and serum IgG trough concentrations; for Hizentra&reg;, it is recommended that patients receive 3 months of I.V. immune globulin before initiating SubQ infusion.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Response to live vaccines may be reduced following immune globulin treatment, refer to package insert or current practice guidelines for recommendations on separation intervals. Products may contain maltose, sorbitol, sucrose, and some packaging may contain latex; consult manufacturer&rsquo;s labeling for additional details.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Products may contain maltose, proline, sorbitol, or sucrose; some packaging may contain latex; consult manufacturers' labeling for additional product-specific information.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13307643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute renal dysfunction (increased serum creatinine, oliguria, acute renal failure, osmotic nephrosis) can rarely occur with intravenous immune globulin administration",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most cases usually occur within 7 days of use (more likely with products stabilized with sucrose). Due to risk of renal dysfunction, use caution in patients with renal disease, diabetes mellitus, volume depletion, sepsis, paraproteinemia, the elderly, and concomitant use of nephrotoxic medications; discontinue if renal function deteriorates.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Infusion-related reactions may occur, characterized by fever, chills, nausea, vomiting, and rarely shock; risk may be increased with initial treatment, when switching brands of immune globulin, and with treatment interruptions of &gt;8 weeks. Stop administration for any signs of infusion reaction.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Noncardiogenic pulmonary edema has been reported with intravenous immune globulin use. Transfusion-related acute lung injury (TRALI) is characterized by severe respiratory distress, pulmonary edema, hypoxemia, and fever in the presence of normal left ventricular function and usually occurs within 1-6 hours after the infusion.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Thrombotic events have been reported with intravenous and subcutaneous administration of immune globulin; patients at risk include those with a history of atherosclerosis, multiple cardiovascular risk factors, impaired cardiac output, hyperviscosity/hypercoagulable disorders, and prolonged periods of immobilization.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hyperproteinemia, increased serum viscosity, and hyponatremia may occur; distinguish true hyponatremia from pseudohyponatremia to prevent a further increase in serum viscosity and a higher risk of thrombotic events.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hypersensitivity and anaphylactic reactions can occur; a severe decrease in blood pressure may rarely occur with anaphylactic reactions; immediate treatment (including epinephrine 1:1000) should be available.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Aseptic meningitis syndrome has been reported with intravenous and subcutaneous administration of immune globulin; symptoms appear within several hours to 2 days of initiation of immune globulin therapy and include severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea, and vomiting. Aseptic meningitis syndrome may occur more frequently with high doses [&ge;1-2 g/kg (product-dependent)]  or rapid infusion. Patients with a migraine history may be at higher risk for aseptic meningitis syndrome.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Intravenous immune globulin has been associated with antiglobulin hemolysis; monitor for signs of hemolytic anemia. High-dose regimens (1 g/kg for 1-2 days) are not recommended for individuals with fluid overload or where fluid volume may be of concern.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Gammagard S/D&reg; and Gammaplex&reg; contain polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. In premature neonates, thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). Infusion of polysorbate 80 containing solutions through polyvinyl chloride tubing may cause DEHP to leach into the solution; in immature animals, exposure to DEHP may adversely affect the development of the male reproductive tract.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F11513254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Live organism vaccination should be withheld for up to 6 months following immune globulin administration.  Live vaccine given immediately prior to immune globulin may require repeat vaccination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Yellow Fever Vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F11513243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11513244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. Immune globulins cross the placenta in increased amounts after 30 weeks gestation. Intravenous immune globulin has been recommended for use in fetal-neonatal alloimmune thrombocytopenia and pregnancy-associated ITP. May also be used in postexposure prophylaxis for rubella (within 72 hours) to reduce the risk of infection and fetal damage in exposed pregnant women who will not consider therapeutic abortion.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13307650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function, urine output, IgG concentrations, hemoglobin and hematocrit, platelets (in patients with ITP); infusion- or injection-related adverse reactions, anaphylaxis, signs and symptoms of hemolysis; blood viscosity (in patients at risk for hyperviscosity); presence of antineutrophil antibodies (if TRALI is suspected); volume status; neurologic symptoms (if aseptic meningitis syndrome suspected); clinical response (as defined by disease state)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SubQ infusion: Monitor IgG trough levels every 2-3 months before/after conversion from I.V.; subcutaneous infusions provide more constant IgG levels than usual I.V. immune globulin treatments",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13307646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replacement therapy for primary and secondary immunodeficiencies and IgG antibodies against bacteria, viral, parasitic, and mycoplasma antigens; interference with F",
"     <sub>",
"      c",
"     </sub>",
"     receptors on the cells of the reticuloendothelial system for autoimmune cytopenias and ITP; provides passive immunity by increasing the antibody titer and antigen-antibody reaction potential",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F13307708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Onset of action: I.V.: Provides immediate antibody levels",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13307647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Consult manufacturers' labeling for additional product-specific information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: I.M.: 23 days; I.V.: IgG concentrations variable: Healthy subjects: 14-24 days; patients with congenital humoral immunodeficiencies: 26-40 days; decreased half-life has been reported to coincide with fever and infection, may be due to hypermetabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: I.M.: Within 48 hours; SubQ: 2.5-2.9 days",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F13307651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/54/16230?source=see_link\">",
"      see \"Immune globulin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     This medication can be administered I.M., I.V., or SubQ with close monitoring during the I.V. or SubQ infusion. May cause nausea; if experienced ask for assistance, do not get up alone. Immediately report chills; chest pain, tightness, or rapid heartbeat; acute back pain; or respiratory difficulty during infusion. Also report decrease in urine output, swelling of extremities, or weight gain; fever and other signs of infection; trouble breathing; increased heart rate, yellowing of skin or eyes, dark urine; stiff neck, severe headache, unexplained drowsiness, or sensitivity to light.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F13307652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DIF: Dual inactivation plus nanofiltration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NF: Nanofiltered",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     S/D: Solvent detergent treated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Octagam&reg; contains sodium 30 mmol/L.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      IgA content:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Carimune&reg; NF: Manufacturer labeling: Trace amounts; others have reported 1000-2000 mcg/mL in a 6% solution (Siegel, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Flebogamma&reg; 5% DIF: &lt;50 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Flebogamma&reg; 10% DIF: &lt;100 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gammagard&reg; Liquid: 37 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gammagard S/D&reg; 5% solution: &lt;1 mcg/mL or &lt;2.2 mcg/mL (product dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gammaked&trade;: 46 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gammaplex&reg;: &lt;10 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gamunex-C&reg;: 46 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hizentra&reg;: &le;50 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Octagam&reg;: &le;200 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Privigen&reg;: &le;25 mcg/mL",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abougergi MS and Kwon JH, \"Intravenous Immunoglobulin for the Treatment of",
"      <i>",
"       Clostridium difficile",
"      </i>",
"      Infection: A Review,\"",
"      <i>",
"       Dig Dis Sci",
"      </i>",
"      , 2011, 56(1):19-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/20924675/pubmed\" id=\"20924675\" target=\"_blank\">",
"        20924675",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Advisory Committee on Immunization Practices (ACIP), Fiore AE, Wasley A, et al, \"Prevention of Hepatitis A Through Active or Passive Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(RR-7):1-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/16708058/pubmed\" id=\"16708058\" target=\"_blank\">",
"        16708058",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Alade SL, Brown RE, and Paquet A Jr, \"Polysorbate 80 and E-Ferol Toxicity,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1986, 77(4):593-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/3960626/pubmed\" id=\"3960626\" target=\"_blank\">",
"        3960626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Subcommittee on Hyperbilirubinemia, \"Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(1):297-316.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/15231951/pubmed\" id=\"15231951\" target=\"_blank\">",
"        15231951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson D, Ali K, Blanchette V, et al, \"Guidelines on the Use of Intravenous Immune Globulin for Hematologic Conditions,\"",
"      <i>",
"       Transfus Med Rev",
"      </i>",
"      , 2007, 21(2 Suppl 1):9-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/17397769/pubmed\" id=\"17397769\" target=\"_blank\">",
"        17397769",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      ASHP Commission on Therapeutics, \"ASHP Therapeutic Guidelines for Intravenous Immune Globulin,\"",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1992, 49(3):652-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/1598949/pubmed\" id=\"1598949\" target=\"_blank\">",
"        1598949",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bassan H and Spirer Z, \"Intravenous Immunoglobulin in Neonatal Myasthenia Gravis,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1999, 135(6):790.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/10586190/pubmed\" id=\"10586190\" target=\"_blank\">",
"        10586190",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bassan H, Muhlbaur B, Tomer A, et al, \"High-Dose Intravenous Immunoglobulin in Transient Neonatal Myasthenia Gravis,\"",
"      <i>",
"       Pediatr Neurol",
"      </i>",
"      , 1998, 18(2):181-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/9535308/pubmed\" id=\"9535308\" target=\"_blank\">",
"        9535308",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blanchette VS, Luke B, Andrew M, et al, \"A Prospective Randomized Trial of High-Dose Intravenous Immune Globulin G Therapy, Oral Prednisone Therapy, and No Therapy in Childhood Acute Immune Thrombocytopenic Purpura,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1993, 123(6):989-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/8229536/pubmed\" id=\"8229536\" target=\"_blank\">",
"        8229536",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      British Committee for Standards in Haematology General Haematology Task Force,  \"Guidelines for the Investigation and Management of Idiopathic Thrombocytopenic Purpura in Adults, Children and in Pregnancy,\"",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2003,  120(4):574-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/12588344/pubmed\" id=\"12588344\" target=\"_blank\">",
"        12588344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations From CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Update: Prevention of Hepatitis A After Exposure to Hepatitis A Virus and in International Travelers. Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2007, 56(41):1080-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/17947967/pubmed\" id=\"17947967\" target=\"_blank\">",
"        17947967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cherin P and Herson S, \"Indications for Intravenous Gammaglobulin Therapy in Inflammatory Myopathies,\"",
"      <i>",
"       J Neurol Neurosurg Psychiatry",
"      </i>",
"      , 1994, (57): 50-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/7964854/pubmed\" id=\"7964854\" target=\"_blank\">",
"        7964854",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dalakas MC and Hohlfeld R, \"Polymyositis and Dermatomyositis,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9388):971-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/14511932/pubmed\" id=\"14511932\" target=\"_blank\">",
"        14511932",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dalakas MC, Illa I, Dambrosia JM, et al, \"A Controlled Trial of High-Dose Intravenous Immune Globulin Infusions as Treatment for Dermatomyositis,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(27):1993-2000.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/8247075/pubmed\" id=\"8247075\" target=\"_blank\">",
"        8247075",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dalakas MC, \"Intravenous Immunoglobulin In Autoimmune Neuromuscular Diseases,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 291(19):2367-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/15150209/pubmed\" id=\"15150209\" target=\"_blank\">",
"        15150209",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Drucker NA, Colan SD, Lewis AB, et al, \"Gamma-Globulin Treatment of Acute Myocarditis in the Pediatric Population,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 1994, 89(1):252-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/8281654/pubmed\" id=\"8281654\" target=\"_blank\">",
"        8281654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eijkhout HW, van Der Meer JW, Kallenberg CG, et al, \"The Effect of Two Different Dosages of Intravenous Immunoglobulin on the Incidence of Recurrent Infections In Patients With Primary Hypogammaglobulinemia. A Randomized, Double-Blind, Multicenter Crossover Trial,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2001, 135(3):165-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/11487483/pubmed\" id=\"11487483\" target=\"_blank\">",
"        11487483",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      English RF, Janosky JE, Ettedgui JA, et al, \"Outcomes for Children With Acute Myocarditis,\"",
"      <i>",
"       Cardiol Young",
"      </i>",
"      , 2004, 14(5):488-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/15680069/pubmed\" id=\"15680069\" target=\"_blank\">",
"        15680069",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Feasby T, Banwell B, Benstead T, et al, \"Guidelines on the Use of Intravenous Immune Globulin for Neurologic Conditions,\"",
"      <i>",
"       Transfus Med Rev",
"      </i>",
"      , 2007, 21(2 Suppl 1):57-107.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/17397768/pubmed\" id=\"17397768\" target=\"_blank\">",
"        17397768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Girish G, Chawla D, Agarwal R, et al, \"Efficacy of Two Dose Regimes of Intravenous Immunoglobulin in Rh Hemolytic Disease of Newborn--a Randomized Controlled Trial,\"",
"      <i>",
"       Indian Pediatr",
"      </i>",
"      , 2008, 45(8):653-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/18723908/pubmed\" id=\"18723908\" target=\"_blank\">",
"        18723908",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gottstein R and Cooke RW, \"Systematic Review of Intravenous Immunoglobulin in Haemolytic Disease of the Newborn,\"",
"      <i>",
"       Arch Dis Child Fetal Neonatal Ed",
"      </i>",
"      ,  2003, 88(1):F6-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/12496219/pubmed\" id=\"12496219\" target=\"_blank\">",
"        12496219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gurcan HM and Ahmed AR, \"Efficacy of Various Intravenous Immunoglobulin Therapy Protocols in Autoimmune and Chronic Inflammatory Disorders,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2007, 41(5):812-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/17440006/pubmed\" id=\"17440006\" target=\"_blank\">",
"        17440006",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hia CP, Yip WC, Tai BC, et al, \"Immunosuppressive Therapy in Acute Myocarditis: An 18 Year Systematic Review,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 2004, 89(6):580-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/15155409/pubmed\" id=\"15155409\" target=\"_blank\">",
"        15155409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hughes RA, Raphael JC, Swan AV, et al, \"Intravenous Immunoglobulin for Guillain-Barre Syndrome,\"",
"      <i>",
"       Cochrane Database of Systematic Reviews",
"      </i>",
"      , 2008, issue 2.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hughes RA, Wijdicks EF, Barohn R, et al, \"Practice Parameter: Immunotherapy for Guillain-Barr&eacute; Syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2003, 61(6):736-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/14504313/pubmed\" id=\"14504313\" target=\"_blank\">",
"        14504313",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      INIS Collaborative Group, Brocklehurst P, Farrell B, et al, \"Treatment of Neonatal Sepsis With Intravenous Immune Globulin,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(13):1201-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/21962214/pubmed\" id=\"21962214\" target=\"_blank\">",
"        21962214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jenson HB and Pollock BH, \"Meta-Analyses of the Effectiveness of Intravenous Immune Globulin for Prevention and Treatment of Neonatal Sepsis,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1997, 99(2):E2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/9099759/pubmed\" id=\"9099759\" target=\"_blank\">",
"        9099759",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klugman D, Berger JT, Sable CA, et al, \"Pediatric Patients Hospitalized With Myocarditis: A Multi-institutional Analysis,\"",
"      <i>",
"       Pediatr Cardiol",
"      </i>",
"      , 2010, 31(2):222-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/19936586/pubmed\" id=\"19936586\" target=\"_blank\">",
"        19936586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koh MJ and Tay YK, \"Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Asian Children,\"",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2010, 62(1):54-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/19811851/pubmed\" id=\"19811851\" target=\"_blank\">",
"        19811851",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kuwabara S, \"Guillain-Barr&eacute; Syndrome: Epidemiology, Pathophysiology and Management,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 2004, 64(6):597-610.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/15018590/pubmed\" id=\"15018590\" target=\"_blank\">",
"        15018590",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leung DY, Kelly CP, Boguniewicz M, et al, \"Treatment With Intravenously Administered Gamma Globulin of Chronic Relapsing Colitis Induced by",
"      <i>",
"       Clostridium difficile",
"      </i>",
"      Toxin,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1991, 118(4 Pt 1):633-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/1901084/pubmed\" id=\"1901084\" target=\"_blank\">",
"        1901084",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Masur H, Kaplan JE, Holmes KK, et al, \"Guidelines for Preventing Opportunistic Infections Among HIV-Infected Persons &minus; 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2002, 137(5 Pt 2):435-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/12617574/pubmed\" id=\"12617574\" target=\"_blank\">",
"        12617574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McFarland LV, Brandmarker SA, and Guandalini S, \"Pediatric",
"      <i>",
"       Clostridium difficile",
"      </i>",
"      : A Phantom Menace or Clinical Reality?\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2000, 31(3):220-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/10997362/pubmed\" id=\"10997362\" target=\"_blank\">",
"        10997362",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miqdad AM, Abdelbasit OB, Shaheed MM, et al, \"Intravenous Immunoglobulin G (IVIG) Therapy for Significant Hyperbilirubinemia in ABO Hemolytic Disease of the Newborn,\"",
"      <i>",
"       J Matern Fetal Neonatal Med",
"      </i>",
"      , 2004, 16(3):163-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/15590442/pubmed\" id=\"15590442\" target=\"_blank\">",
"        15590442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morici MV, Galen WK, Shetty AK, et al, \"Intravenous Immunoglobulin Therapy for Children With Stevens-Johnson Syndrome,\"",
"      <i>",
"       J Rheumatol",
"      </i>",
"      , 2000, 27(10):2494-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/11036849/pubmed\" id=\"11036849\" target=\"_blank\">",
"        11036849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Newburger JW, Takahashi M, Gerber MA, et al, \"Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004,  114(6):1708-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/15574639/pubmed\" id=\"15574639\" target=\"_blank\">",
"        15574639",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      NIH Consensus Conference, \"Intravenous Immunoglobulin, Prevention and Treatment of Disease,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 1990, 264(24):3189-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/2255028/pubmed\" id=\"2255028\" target=\"_blank\">",
"        2255028",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ohlsson A and Lacy J, \"Intravenous Immunoglobulin for Preventing Infection in Preterm and/or Low Birth Weight Infants (Review),\"",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2010, Issue 5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ohlsson A and Lacy J, \"Intravenous Immunoglobulin for Suspected or Subsequently Proven Infection in Neonates,\"",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2010, (3):CD001239.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/20238315/pubmed\" id=\"20238315\" target=\"_blank\">",
"        20238315",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patwa HS, Chaudhry V, Katzberg H, et al, \"Evidence-Based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromuscular Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2012, 78(13):1009-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/22454268/pubmed\" id=\"22454268\" target=\"_blank\">",
"        22454268",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009, 37, 56-61, 444-455, 718, 721.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sansome A and Dubowitz V, \"Intravenous Immunoglobulin in Juvenile Dermatomyositis--Four Year Review of Nine Cases,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1995, 72(1):25-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/7717731/pubmed\" id=\"7717731\" target=\"_blank\">",
"        7717731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Siegel J, \"Immune Globulins: Therapeutic, Pharmaceutical,  Cost and Administration Considerations,\"",
"      <i>",
"       Pharmacy Practice News",
"      </i>",
"      , 2011, 20-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Siegel J, \"Immunoglobulins and Obesity,\"",
"      <i>",
"       Pharmacy Practice News",
"      </i>",
"      ,  2010, 37:1.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tagher RJ, Baumann R, and Desai N, \"Failure of Intravenously Administered Immunoglobulin in the Treatment of Neonatal Myasthenia Gravis,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1999, 134(2):233-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/9931536/pubmed\" id=\"9931536\" target=\"_blank\">",
"        9931536",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tomblyn M, Chiller T, Einsele H, et al, \"Guidelines for Preventing Infectious Complications Among Hematopoietic Cell Transplantation Recipients: A Global Perspective,\"",
"      <i>",
"       Biol Blood Marrow Transplant",
"      </i>",
"      , 2009, 15(10):1143-238.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/19747629/pubmed\" id=\"19747629\" target=\"_blank\">",
"        19747629",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tristani-Firouzi P, Petersen MJ, Saffle JR, et al, \"Treatment of Toxic Epidermal Necrolysis With Intravenous Immunoglobulin in Children,\"",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2002, 47(4):548-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/12271299/pubmed\" id=\"12271299\" target=\"_blank\">",
"        12271299",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations Consensus Statement,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 1995, 273(23):1865-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/7776504/pubmed\" id=\"7776504\" target=\"_blank\">",
"        7776504",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watson JC, Hadler SC, Dykewicz CA, et al, \"Measles, Mumps, and Rubella &minus; Vaccine Use and Strategies for Elimination of Measles, Rubella, and Congenital Rubella Syndrome and Control of Mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 1998, 47(RR-8):1-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/55/15226/abstract-text/9639369/pubmed\" id=\"9639369\" target=\"_blank\">",
"        9639369",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wimperis J, Lunn M, Jones A, et al, \"National Health Service. Clinical Guidelines for the Use of Immunoglobulin Use: Second Edition Update, July 2011.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83878 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-A7B94B43F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_55_15226=[""].join("\n");
var outline_f14_55_15226=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15601262\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513229\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513233\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513234\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307640\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307724\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307648\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513299\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513236\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15841018\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307649\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513264\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307645\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307641\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513231\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513251\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307642\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307672\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307643\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299513\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513254\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513243\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11513244\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307650\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307646\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307708\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307647\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307651\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13307652\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/83878\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/83878|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/23/1402?source=related_link\">",
"      Immune globulin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/54/16230?source=related_link\">",
"      Immune globulin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_55_15227="Exploratory questions for advanced care planning";
var content_f14_55_15227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PALC%2F87344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PALC%2F87344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Helpful exploratory questions that can be used in palliative care for the advanced care planning process",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Have you had someone close to you/had your own experience with serious illness or death? If you were in that situation (again), what would you hope for?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can you think of circumstances in which living longer might be more burdensome than dying?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        When you think of becoming critically ill, what worries you the most?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If you were to become critically ill and unable to speak on your own behalf, is there anyone you trust to make medical decisions for you? Are your preferences documented/in writing?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Have you given any thought to whether you'd like cardiopulmonary resuscitation if you were to die suddenly? May I explain what CPR entails in your circumstances and what are your estimated chances of benefiting from it?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        What kind of treatments would you want, and which ones might you decline if you were to become critically ill and unable to speak for yourself?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_55_15227=[""].join("\n");
var outline_f14_55_15227=null;
var title_f14_55_15228="Lead chelating agents B";
var content_f14_55_15228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristic features and adverse effects of chelating agents used in the treatment of childhood lead poisoning",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        CaNa",
"        <sub>",
"         2",
"        </sub>",
"        EDTA",
"       </td>",
"       <td>",
"        Only removes lead from the extracellular compartment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May increase CNS lead burden",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Must be given after BAL has been administered in patients with severe lead intoxication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May cause hypercalcemia, renal dysfunction, excretion of divalent minerals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        BAL*",
"       </td>",
"       <td>",
"        Must be administered intramuscularly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can be administered in the presence of renal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contraindicated in individuals with peanut allergy or hepatic insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May cause hemolysis in individuals with G6PD deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Causes vomiting if administered with iron",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        D-penicillamine",
"       </td>",
"       <td>",
"        Not FDA approved for treatment of lead poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administered orally",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absorption impaired by iron, antacids, and food",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contraindicated in penicillin allergy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid giving with dairy products or iron",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May cause rash, nausea, vomiting, leukopenia, thrombocytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        DMSA",
"       </td>",
"       <td>",
"        FDA approved for treatment of lead poisoning in children with BLL &gt;45 &micro;g/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Administered orally",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May cause elevated LFT's",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May cause hemolysis in individuals with G6PD deficiency",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * British anti-Lewisite.",
"    </div>",
"    <div class=\"reference\">",
"     file://www.atsdr.cdc.gov/HEC/CSEM/lead/treatment_management.html#Table2",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_55_15228=[""].join("\n");
var outline_f14_55_15228=null;
var title_f14_55_15229="Free water reabsorption";
var content_f14_55_15229=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F55579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F55579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Free water reabsorption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 200px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Block diagram showing the relationship in a concentrated urine between the urine volume and its two components: one containing all of the urinary solute in a solution that is isosmotic to plasma (the osmolal clearance); and one consisting of solute-free water that has been reabsorbed to raise the urine osmolalitu above that in the plasma (the free water reabsorption).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Rose, BD, Am J Med 1986; 81:1033.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_55_15229=[""].join("\n");
var outline_f14_55_15229=null;
var title_f14_55_15230="Duke Treadmill Score and prognosis by gender";
var content_f14_55_15230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Predictive value of Duke Treadmill Score is variable according to gender",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 539px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier curves for two-year survival in 2249 men (top panel) and 976 women (bottom panel) with chest pain and suspected coronary disease with low (&ge;+5), moderate (-10 to +4), and high risk (&le;-11) Duke treadmill scores. The treadmill score effectively risk stratified men but not women. A possible explanation for the lack of predictive value in women is that the mean age was 51 years, an age at which there is a low frequency of clinically important CHD in women.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Alexander, KP, Shaw, LJ, Delong, ER, et al, J Am Coll Cardiol 1998; 32:1657.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_55_15230=[""].join("\n");
var outline_f14_55_15230=null;
var title_f14_55_15231="CMV retinitis";
var content_f14_55_15231=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F60120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F60120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Cytomegalovirus retinitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Retinitis along a vascular distribution as is typical of cytomegalovirus infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James T Rosenbaum, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_55_15231=[""].join("\n");
var outline_f14_55_15231=null;
